Curriculum Vitae and Bibliography
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC
Personal Information Work Address: Mayo Clinic Scottsdale 13400 E Shea Blvd Scottsdale, AZ 85259-5499 Email Address: [email protected]
Present Academic Rank and Position Professor of Medicine - Mayo Clinic College of Medicine and Science 01/2006 - Present
Consultant - Division of Hematology/Oncology, Department of Internal Medicine, 07/2008 - Present Mayo Clinic, Scottsdale, Arizona
Vasek and Anna Maria Polak Professor of Cancer Research - Department of 2009 - Present Education Administration, Mayo Clinic College of Medicine and Science
Full Faculty Privileges - Mayo Clinic Graduate School of Biomedical Sciences, 10/2010 - Present Mayo Clinic College of Medicine and Science
Endowed Director - Mayo Clinic in Arizona, Center for Individualized Medicine, 2015 - Present Carlson and Nelson, Mayo Clinic, Scottsdale, Arizona
Consultant (Joint Appointment) - Department of Medical Genetics, Mayo Clinic, 06/2016 - Present Rochester, Minnesota
Education Aberdeen University Medical School, United Kingdom - MB ChB 1984 Glasgow Royal Infirmary, Glasgow, United Kingdom - Internship 1984 - 1985 Queen's University - Resident, Internal Medicine 1985 - 1988 University of Toronto - Fellow, Hematology 1988 - 1990 New England Medical Center, Boston, Massachusetts - Fellow, MRC Research 1990 - 1992 Richard Ivey School of Business, University of Western Ontario - MBA 2002
Certification Board Certifications Royal College of Physicians and Surgeons, Canada FRCP (C) in Internal Medicine 1989 - Present FRCP (C) in Hematology 1990 - Present Royal College of Physicians and Surgeons, United Kingdom Member (MRCP)/General Medicine 1989 - Present Mayo Clinic Quality Academy Mayo Clinic Quality Fellow: Bronze Level Certification 2011
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 2 of 53
Honors and Awards Scott-Whitmore Chair in Hematology and Gene Therapy - University of Toronto 1999 - 2005 Canada's Top 40 Under 40 - Awarding Organization 2002 Vasek and Anna Maria Polak Professor of Cancer Research - Mayo Clinic 02/2010 College of Medicine and Science America's Top Doctors - Castle Connolly Medical Ltd. 2014 America's Top Doctors - Castle Connolly Medical Ltd 2015
Previous Professional Positions and Major Appointments Assistant Professor - Department of Medicine, University of Toronto, Toronto, 1992 - 1999 Ontario
Head, Experimental Therapeutics - Toronto General Hospital Research Institute, 1999 - 2001 Toronto, Ontario
Associate Professor - Department of Medicine, University of Toronto, Toronto, 1999 - 2005 Ontario
Director - Toronto General Hospital Research Institute, Toronto, Ontario 2000 - 2004
Board Member - Toronto General and Western Hospital Foundation, Toronto, 2000 - 2005 Ontario
Director - McLaughlin Centre for Molecular Medicine, University of Toronto, 2002 - 2005 Toronto, Ontario
Senior Associate Consultant - Division of Hematology/Oncology, Department of 2005 - 07/2008 Internal Medicine, Mayo Clinic, Scottsdale, Arizona
Professor - Department of Medicine, University of Toronto, Toronto, Ontario 2005 - 2009
Medical Director - Clinical Cancer Research Unit, Mayo Clinic, Scottsdale, Arizona 2008 - 07/2010
Dean for Research - Mayo Clinic in Arizona, Mayo Clinic, Scottsdale, Arizona 2010 – 2015
American Society of Hematology - Committee on Investment and Audit 2014-2016
Corporate Board Member – Oncospire Inc. 2015 - Present
Corporate Board Member – Oneome Inc. 2016 - Present
Advisory Board – McLaughlin Center for Molecular Medicine, 2017 - Present University of Toronto
Advisory Board – Helix Inc. 2016 – Present
Non Executive Board member – Genomics England 2017 - Present
Professional and Community Memberships, Societies, and Services
Professional Memberships and Services
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 3 of 53
American Society of Clinical Oncology Member 2005 - Present American Society of Hematology Member 2006 - Present Committee on Investment and Audit Member 2014 - 2016 Hema-Quebec Scientific Advisory Board Member 1999 - 2002 International Myeloma Foundation Scientific Advisory Board Member 2005 - Present International Society for Hematotherapy and Graft Engineering Gene Therapy Committee Member 1997 - 2003 Leukemia & Lymphoma Society Medical and Scientific Affairs Committee Member 2011 - 2015 TRP Peer Review Panel: CLL, Lymphoma, Myeloma Chair 2012 - 2015 McCarty Cancer Foundation Scientific Advisory Board Member 1997 - 2006 Multiple Myeloma Research Consortium Steering Committee Member 2004 - 2010 Multiple Myeloma Research Foundation Scientific Advisory Board Member 1998 - Present Myeloma UK Advisory Board Member 2012 - Present Peer Review Panel Member 2009 - 2012 National Cancer Institute of Canada Clinical Trials Group Myeloma Site Group Head 2004 - 2006 National Institutes of Health National Cancer Institute Cancer Therapy Evaluation Program External Reviewer 2006 - Present Developmental Therapeutics Study Section Member 2009 - 2011 Chair 2011 - 2013 Subcommittee D Parent Committee
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 4 of 53
Member 2002 - 2005 Special Emphasis Panel Chair 2005 - 2006 Royal College of Physicians and Surgeons of Canada Fellow 1989 - Present Society of Hematologic Oncology Scientific Committee Member 2014 - Present Toronto Hospital Animal Care Committee Member 1998 - 2001
University of Toronto Institute of Medical Science Member 1996 - 2008
Journal Responsibilities
Journal Editorial Responsibilities American Society of Hematology (ASH) Clinical News Editorial Board Member 2014 - Present Blood Associate Editor 01/2008 - 12/2013 Current Gene Therapy Editorial Board Member 01/2001 - 01/2003 Targeted Therapies in Oncology Editorial Board Member 01/2014 - Present
Journal Other Responsibilities Annals of Internal Medicine Journal Reviewer Annals of Oncology Journal Reviewer Biology of Blood and Marrow Transplantation Journal Reviewer Blood Journal Reviewer Bone Marrow Transplantation Journal Reviewer British Journal of Haematology Journal Reviewer Cancer Detection and Prevention Journal Reviewer Cancer Research Journal Reviewer Clinical Cancer Research
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 5 of 53
Journal Reviewer Cytokines Journal Reviewer Experimental Hematology Journal Reviewer Human Gene Therapy Journal Reviewer Journal of Clinical Oncology Journal Reviewer Journal of Hematotherapy Journal Reviewer Leukemia Journal Reviewer Molecular Therapy Journal Reviewer New England Journal of Medicine Journal Reviewer Proceedings of the National Academy of Sciences of the United States of America Journal Reviewer The Journal of Clinical Investigation Journal Reviewer
Educational Activities
Teaching Intramural Emerging Therapies and Treatment Strategies in the Management of 02/01/2012 Relapsed/Refractory Multiple Myeloma VA Medical Center Rounds Washington, District of Columbia
Advances in Biology and Therapy of Myeloma 05/03/2012 Queen Elizabeth II Health Science Center Rounds Halifax, Nova Scotia, Canada
Advances in Biology and Therapy of Myeloma 05/04/2012 Ottawa General Hospital Blood and Marrow Transplant Rounds Ottawa, Ontario, Canada
Genome Based Therapeutic Insights Into Myeloma 07/25/2012 Grand Rounds MD Anderson Cancer Center Houston, Texas
Therapeutic and Biologic Advances in Myeloma 08/24/2012 Grand Rounds Emory University School of Medicine Atlanta, Georgia
How Genomics Influences Therapy in Myeloma 09/10/2012 Arizona Cancer Center at the University of Arizona: Cancer Biology Seminar Series Tucson, Arizona
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 6 of 53
Genomic Guided therapeutics in Myeloma 01/15/2013 Grand Rounds University of North Carolina Lineberger Cancer Center Chapel Hill, North Carolina
Advances in Myeloma Biology and Therapy 01/18/2013 Grand Rounds Princess Margaret Hospital Toronto, Ontario, Canada
Genomics Driven Myeloma Therapeutics 02/22/2013 Hematology Rounds Southern Alberta Cancer Research Institute (SACRI) Calgary, Alberta, Canada
Genomics Guided Advances in Myeloma Biology and Therapy 04/11/2013 Grand Rounds Columbia University Medical Center New York, New York
Multiple Myeloma 04/18/2013 Grand Rounds Cone Health Cancer Center Greensboro, North Carolina
Second Opinion: An Interactive Grand Rounds Series; Clinical Investigators 05/03/2013 Provide Their Perspectives on Challenging Cases and Controversies in the Management of Multiple Myeloma Illinois Cancer Center Peoria, Illinois
Genome Guided Therapeutics in Myeloma 05/08/2013 Division of Hematology Lecture Series, McGill University Health Center Montreal, Quebec, Canada
Multiple Myeloma 05/22/2013 Grand Rounds Maimonides Medical Center Brooklyn, New York
Multiple Myeloma 08/16/2013 Tumor Board Rounds Martha Jefferson Hospital Charlottesville, Virginia
Emerging Strategies in the Management of Multiple Myeloma 09/17/2013 Hospital Grand Rounds Doctors Medical Center San Pablo, California
Focus on Multiple Myeloma 01/30/2014 Hospital Rounds Thomas Johns Cancer Hospital Richmond, Virginia
Emerging Strategies in the Management of Multiple Myeloma 01/31/2014
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 7 of 53
Oncology Exchange Sponsored Rounds Mary Washington Hospital Fredericksburg, Virginia
Myeloma Genomics Guided Therapeutics 01/2015 Grand Rounds Memorial Sloan Kettering Cancer Center New York, New York
Mentorship Plowright, Elizabeth (MSc Student) 01/1997 - 01/1999 Description: University of Toronto, Institute of Medical Science (FGFR3 in the pathogenesis of myeloma) Current Status: Outcome:
Mandelbaum, S (MSc Student) 01/1997 - 01/2000 Description: University of Toronto Surgical Scientist Fellow Institute of Medical Science (Immunoencapsulation of gene modified cells for cancer immunotherapy) Current Status: Outcome:
Pollett, Jonathan (Ph.D. Student) 01/1998 - 01/2004 Description: University of Toronto, Institute of Medical Science, (RU486-inducible retrovirus-mediated caspase 3 overexpression in myeloma cells) Current Status: Outcome:
Voralia, Michael (Postdoctoral Fellow) 01/1999 - 01/2002 Description: University of Toronto, Hematology Fellow Elective (Role of BLyS in myeloma) Current Status: Outcome:
Paterson, Joshua (Ph.D. Student) 01/2000 - Present Description: University of Toronto, Institute of Medical Science (Maf promoters in myeloma) Current Status: Outcome:
Ghandi, Sonal (Summer Student) 01/2000 Description: University of Toronto Current Status: Outcome:
Stern, Daniel (MSc Student) 01/2000 Description: University of Toronto - (XBP and Myeloma) Current Status: Outcome:
Trieu, Young (Undergraduate Student) 01/2000 - 01/2001 Description: University of Toronto Current Status: Outcome:
Adesanya, Tayo (Summer Student) 01/2001 Description: University of Western Ontario Current Status:
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 8 of 53
Outcome:
Klinghoffer, Zack (Summer Student) 01/2001 Description: University of Toronto Current Status: Outcome:
Klinghoffer, Zack (Undergraduate Student) 01/2001 Description: University of Toronto Current Status: Outcome:
Preston, Mark (Summer Student) 01/2001 Description: University of Western Ontario Current Status: Outcome:
Onwuazor, Obia (MSc Student) 01/2001 - 01/2003 Description: University of Toronto, Institute of Medical Science (Mutation analysis of fibroblast growth factor receptor 3 in multiple myeloma patients) Current Status: Outcome:
Stern, Daniel (Summer Student) 01/2001 - 01/2003 Description: Queen's University Current Status: Outcome:
Trieu, Young (MSc Student) 01/2001 - 01/2003 Description: University of Toronto, Institute of Medical Science (Adenovirus- mediated gene delivery of the soluble IL-13 decoy receptor inhibits Hodgkin lymphoma growth) Current Status: Outcome:
Wechalekar, Ash (Postdoctoral Fellow) 01/2001 - 01/2003 Description: University of Toronto Bone Marrow Transplant Fellow Current Status: Outcome:
Adesanya, Tayo (Summer Student) 01/2002 Description: University of Western Ontario Current Status: Outcome:
Zaman, Faraz (MSc Student) 01/2002 - 01/2005 Description: University of Toronto, Institute of Medical Science (Maf and myeloma) Current Status: Outcome:
Mikhael, Joseph (Postdoctoral Fellow) 01/2003 - 01/2004 Description: University of Toronto, Hematology Fellow Elective Current Status: Outcome:
Jaksic, Wilfrid (Postdoctoral Fellow) 01/2004 - 01/2005 Description: University of Toronto Bone Marrow Transplant Fellow Current Status: Outcome:
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 9 of 53
Tiedeman, Roger (Postdoctoral Fellow) 01/2005 - 01/2008 Description: Cyclin D2 inhibitors in myeloma Current Status: Outcome:
Sebag, Michael (Postdoctoral Fellow) 01/2005 - 01/2009 Description: Mouse models of myeloma Current Status: Outcome:
Egan, Jan (Postdoctoral Fellow) 01/2009 - 01/2012 Description: Whole Genome Sequencing in Myeloma Current Status: Outcome:
Boczek, Nicole (Mayo Ph.D. Student) 03/2011 Description: Mayo Graduate School Ph.D Student Rotation Current Status: Outcome:
Kortum, Klaus (Research Fellow) 03/2012 - Present Description: Whole Genome Sequencing in Myeloma Current Status: Outcome:
Orzechowski, Amanda (Ph.D. Student) 01/2014 - 02/2014 Description: Mayo Graduate School PhD Student Rotation Current Status: Outcome:
Miller, Amber (Postdoctoral Fellow) 01/2016 - Present Description: Neoantigens in Oncolytic virotherapy Current Status: Outcome:
Institutional/Departmental Administrative Responsibilities, Committee Memberships, and Other Activities Mayo Clinic Mayo Clinic Board of Governors The Named Professorship Committee Member 03/2011 - Present Mayo Clinic Committees Mayo Clinic Research Advisory Group Scientific Advisory Council Member 03/2011 - Present Mayo Clinic Research Committee Member 2010 - 2015 Executive Research Committee Member 2011 - 2015
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 10 of 53
Medical Relations Committee Member 01/2014 - Present Mayo Clinic in Arizona Department of Internal Medicine Division of Hematology/Oncology Hematology Disease Oriented Group Member 2007 - Present Chair 2007 - 2010 Mayo Clinic Arizona Committees Executive Operations Team - Arizona Member 2011 - 2015 Cancer Center Committee Member 2007 - 2012 Clinical Practice Committee - Arizona Member 2012 - 2015 Collaboration and Business Development Coordination Council Member 2006 - 2011 Division Chairs Meeting Member 2010 - Present Space and Capital Committee Member 2012 - 2015 Research Operations Management Team Member 2010 - 2015 Clinical Research Subcommittee Member 2007 - 2010
Presentations Extramural National or International
Oral
Novel Agents in Myeloma Present and Future 01/13/2012 Mayo Clinic Clinical Hematology and Oncology 2012: the 9th Annual Mayo Review Scottsdale, Arizona
Plasma Cell Disorders (Myeloma) 01/21/2012 American Society of Hematology 2012 Highlights of ASH in North America Austin, Texas
Plasma Cell Disorders (Myeloma) 01/28/2012 American Society of Hematology 2012 Highlights of ASH in North America
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 11 of 53
Las Vegas, Nevada
How to Prepare a Manuscript for Submission to Blood 03/04/2012 2012 Highlights of ASH in Asia Singapore
Plasma Cell Disorders: Myeloma 03/04/2012 2012 Highlights of ASH in Asia Singapore
Clinical Trials and New Drugs 03/24/2012 International Myeloma Foundation: Seattle Patient & Family Seminar Seattle, Washington
Relapsed/Refractory Disease 03/31/2012 Multiple Myeloma Research Foundation: Clinical Insights in Multiple Myeloma Patient & Caregiver Symposium San Francisco, California
The Role of IMiD's in the Management of Hematological Malignancies 04/16/2012 Celgene Summit, New Jersey
Future Trends in Myeloma 04/25/2012 Onyx San Francisco, California
Multiple Myeloma and Novel Agents 04/28/2012 XXIV World Congress of the International Society of Hematology Cancun, Mexico
PX-171-003-A1, an Open Label, Single-Arm Phase 2 Study of Carfilzomib in 04/28/2012 Patients with Relapsed and Refractory Multiple Myeloma: Long Term Follow-up and Subgroup Analysis XXIV World Congress of the International Society of Hematology Cancun, Mexico
Myeloma Update 05/03/2012 Queen Elizabeth II Health Science Center Multiple Myeloma Patient Support Group Halifax, Nova Scotia, Canada
Advances in Biology and Therapy of Myeloma 05/05/2012 Northern Ontario Cancer Center Hematology Symposium Sudbury, Ontario, Canada
Updates on the Treatment of Multiple Myeloma 05/11/2012 Greek Myeloma Annual Study Group Meeting Athens, Greece
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 12 of 53
Targeted Therapy in Myeloma 05/13/2012 The University of Hong Kong, Department of Medicine: 17th Hong Kong Medical Forum Hong Kong
How I Treat Myeloma 05/16/2012 Janssen Educational Meeting to Melbourne Hematologists Melbourne, Victoria, Australia
What is a High Risk Patient? Can the Biology of Risk Inform the Treatment? 05/19/2012 2012 Managing Multiple Myeloma (M3) Weekend Symposium/Workshop Sydney, NSW, Australia
The High Risk Multiple Myeloma Patient 05/20/2012 Case Study/Panel Discussion 2012 Managing Multiple Myeloma (M3) Weekend Symposium/Workshop Sydney, NSW, Australia
Phase 1 Trial of Obatoclax Mesylate in Combination with Bortezomib for Treatment 06/02/2012 of Relapsed Multiple Myeloma 2012 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, Illinois
Molecular Pathways in Multiple Myeloma 09/14/2012 Multiple Myeloma in 2012 and Beyond: An Expert Panel Discussion Scottsdale, Arizona
Relapsed/Refractory Disease: The Role of Available ImiDs 09/14/2012 Multiple Myeloma in 2012 and Beyond: An Expert Panel Discussion Scottsdale, Arizona
Does Cereblon Explain Everything About IMiDs? 10/06/2012 10th International Workshop on Myeloma Pharmacogenomics & Novel Therapeutics Phoenix, Arizona
Autologous SCT 10/10/2012 Hematologic Malignancies 2012 - 8th International Conference Houston, Texas
From Bench to Bedside: The Future Management of Multiple Myeloma 10/17/2012 Perspectives in Hematological Malignancies Conference Salamanca, Spain
Non-stem Cell Transplantation Candidates: Treatment Strategies - State of the Art 10/17/2012 Perspectives in Hematological Malignancies Conference Salamanca, Spain
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 13 of 53
Cereblon-ImiDs Partner 10/25/2012 Lymphoma & Myeloma 2012: An International Congress on Hematologic Malignancies New York, New York
Translational Research: A Mayo Clinic Perspective 10/30/2012 Laboratory Products Association Annual Meeting Scottsdale, Arizona
Myeloma: A Glimpse at the Future 11/03/2012 Proteasome Inhibitor Global Franchise Advisory Panel Washington, District of Columbia
Myeloma Relapse 11/17/2012 IMF Patient Myeloma Meeting Scottsdale, Arizona
Myeloma: The Year in Review 11/17/2012 Year in Review - A Multitumor CME Symposia Series Focused on Key Clinical Presentations and Papers in Oncology Washington, District of Columbia
Post-transplant Maintenance: Predictors of Response to Treatment 12/07/2012 International Second OpinionA 2-part Friday Satellite Symposia Series preceding the ASH Meeting 54th American Society of Hematology (ASH) Annual Meeting Atlanta, Georgia
Update on Risk Assessment Strategies in the Treatment of Multiple Myeloma 03/02/2013 6th Symposium on Emerging Treatments and Advances in Novel Cancer Therapies for Practicing Physicians and Healthcare Professionals Dallas, Texas
Advances in the Management of Relapsed/Refractory Multiple Myeloma 03/14/2013 Hematology Highlights 2013: Expert Reviews of the Annual Hematology Meeting Las Vegas, Nevada
Current Paradigm in Myeloma Therapy: Biology of Immune Modulators 04/06/2013 XIV International Myeloma Workshop Kyoto, Japan
Relapsed Multiple Myeloma: The Pathophysiology of Treatment Resistance-The 04/07/2013 Role of Cereblon XIV International Myeloma Workshop Kyoto, Japan
Genetics and Genomics in Myeloma 04/26/2013
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 14 of 53
17th Annual Update in Hematologic Malignancies at Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland
Challenging Cases in Multiple Myeloma 04/27/2013 38th Annual ONS Congress Washington, District of Columbia
Remaining Hot Questions in Multiple Myeloma 08/09/2013 EPIC: Multiple Myeloma in 2013 and Beyond: An Expert Roundtable Scottsdale, Arizona
Big Data in Uncommon Cancers 09/24/2013 Multiple Myeloma Research Foundation New York, New York
Carfilzomib 10/05/2013 European School of Hematology (ESH) Meeting Dublin, Ireland
Understanding the Cellular Targets of IMID's and the Relevance to Clinical Efficacy 10/05/2013 Satellite Symposium at ESH Meeting Dublin, Ireland
Understanding Molecular Pathogenesis and Biological Behavior of Multiple 10/11/2013 Myeloma to Further Improve is Clinical Outcome 75th Annual Meeting of the Japanese Society of Hematology (JSH) Sapporo, Japan
Treatment Options for Newly Diagnosed Patients 11/02/2013 Multiple Myeloma Research Foundation (MMRF) Clinical Insights into Myeloma Scottsdale, Arizona
Emerging Strategies in the Management of Multiple Myeloma 11/09/2013 Oncology Exchange Multiple Myeloma Symposium Jacksonville, Florida
Genomic Studies in Multiple Myeloma and Aspects of Clonal Evolution 11/16/2013 Association for Molecular Pathology Annual Meeting Phoenix, Arizona
Multiple Myeloma 11/23/2013 Research to Practice Second Annual Year in Review Symposium Los Angeles, California
Maintenance/Consolidation Therapy and Impact of Adverse Cytogenetics 12/06/2013 Research to Practice Investigator Perspectives on Practical Issues and Research Questions in Multiple Myeloma New Orleans, Louisiana
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 15 of 53
Novel Therapies 01/25/2014 Clinical and Multidisciplinary Hematology and Oncology 2014: 11th Annual Mayo Clinic Annual Review Scottsdale, Arizona
Proteasome Inhibitors: What have we learned during the past ten years? 03/27/2014 1st Annual Multiple Myeloma Summit Whistler, British Columbia, Canada
Next Generation Sequencing 04/05/2014 University Clinics Wurzburg International Meeting on Multiple Myeloma Wurzburg, Germany
Cereblon, Ikaros and Clinical Outcomes 04/12/2014 Myeloma 2014 Workshop Boston, Massachusetts
E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) 06/02/2014 versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma MM Oral Abstract Presentation ASCO Annual Meeting Chicago, Illinois
E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide (MPT) 06/14/2014 versus melphalan, prednisone, and lenalidomide (MPR) in newly diagnosed multiple myeloma MM Oral Abstract Presentation 19th Congress of the European Hematology Association Plenary Session Milan, Italy
The Genome and Myeloma Therapeutics 06/14/2014 19th Congress of the European Hematology Association Plenary Session Milan, Italy
Mastering Clinical Challenges in Relapsed/Refractory Multiple Myeloma: Optimizing 07/26/2014 Outcomes through Personalized Care Workshop MedIQ Atlanta, Georgia
Optimizing Outcomes Through Personalized Multiple Myeloma Treatment: A 08/02/2014 Regional Workshop Series for the Entire Care Team CME/CE Workshop MedIQ Birmingham, Michigan
Myeloma 08/07/2014
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 16 of 53
24th Mayo Clinic Annual Hematology/Oncology Reviews Amelia Island, Florida
Mastering Clinical Challenges in Relapsed/Refractory Multiple Myeloma: Optimizing 09/13/2014 Outcomes through Personalized Care Workshop MedIQ Garden Grove, California
Relapsed/Refractory Disease: The Evolving Role of Available IMiDs and PIs 09/13/2014 EPIC Multiple Myeloma in 2014 and Beyond: An Expert Roundtable Scottsdale, Arizona
Is whole genome sequencing helpful in routine care of newly diagnosed myeloma? 09/19/2014 The Society of Hematologic Oncology Annual Meeting (SOHO) Houston, Texas
Multiple Myeloma - State of the Art Therapy 10/18/2014 Clinical Hematology Updates with a Focus on Lymphoid Malignancies 2014 ASH State-of-the-Art Symposium Baltimore, Maryland
iMiDs: Mode of Action and Future Applications 10/23/2014 Lymphoma and Myeloma 2014: An International Congress on Hematologic Malignancies New York, New York
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and 12/07/2014 Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study American Society of Hematology (ASH) Chicago, Illinois
Research Interests 1. Translational Research in Multiple Myeloma: Dr. Stewart has both basic and clinical research interests in identifying novel targets for therapy in multiple myeloma. He has been continuously funded by national agencies since 1992. His research is currently supported by the National Cancer Institute, Multiple Myeloma Research Foundation, Leukemia & Lymphoma Society and by partnerships with the pharmaceutical industry for clinical trials. The research programs can be divided into three broad categories:
2. Study of the Cancer Genome: Recently we have focused on the use of high throughput druggable genome RNAi screening in the presence or absence of therapeutic agents such as bortezomib and lenalidomide. This work will lead to the identification of targets which when suppressed sensitize patients’ myeloma cells to the effects of chemotherapy. We have worked extensively in next generation sequencing of myeloma cells in patients who have become resistant to chemotherapy drugs in an attempt to identify mechanisms of resistance. Our first whole human genome sequence was completed in June of 2009. Recently we have developed and taken to clinical utility a myeloma gene panel, described clonal heterogeneity and tides in Myeloma and uncovered the role of cereblon in immune modulating drug activity.
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 17 of 53
3. Drug Development: We have performed high throughput screens of small molecules to identify inhibitors of myeloma targets. We have been successful in these screens in identifying a number of small molecules which when applied to myeloma cells resulted in cell death. We have employed a medicinal chemistry approach to the development of analogues for these molecules and will pursue these into preclinical testing and subsequently clinical trials.
4. Clinical Trials: Dr. Stewart is lead investigator on numerous clinical trials, including first in human phase 1 and large international randomized phase 3 trials. Novel agents / targets studied recently include eg. Carfilzomib, Pomalidomide, Isatuximab, Selinexor, Afuresterib, Dinaciclib, PDL-1, AKT, Glutaminase and FGFR3 inhibitors
Research Grants Awarded
Active Grants Federal Program Translation of Novel Therapeutic Targets in Multiple Myeloma. Funded 01/2013 - 12/2017 Director / by National Cancer Institute. (R01 R01 CA167511) Principal Investigator
Program The Role of Cereblon Pathways in Myeloma. Funded by National 04/2014 - 03/2019 Director / Cancer Institute. (R01 R01 CA183968) Principal Investigator
Co-Investigator CHEK1 and WEE1 Inhibition as Therapeutic Strategies in AML. Funded 07/2013 - 06/2018 by National Cancer Institute. (R01 CA178979)
Co-Investigator DEVELOPMENT RESEARCH PROGRAM: Mayo Clinic Multiple 09/2015 - 08/2020 Myeloma SPORE. Funded by National Cancer Institute. (P50 CA186781-01A1)
Co-Investigator PROJECT 4 Clonal Evolution in Multiple Myeloma: Mayo Clinic Multiple 09/2015 - 08/2020 Myeloma SPORE. Funded by National Cancer Institute. (P50 CA186781-01A1)
Foundation Collaborator Immunomodulatory drugs' target cereblon and its downstream 10/2013 - 09/2017 substrates. Funded by The Leukemia & Lymphoma Society. (6048-14)
Industry Program PX-171-001 A Phase I Study of the Safety and Pharmacokinetics of 02/2006 - 01/2008 Director / Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Principal Patients with Hematological Malignancies: Two Week Cycle. Funded by Investigator Proteolix, Inc.
Program HGS1012-C1055 Phase 2 study of Mapatumumab in combination with 08/2006 - 07/2008 Director / Bortezomib in pts with Multiple Myeloma. Funded by Human Genome Principal Sciences, Inc.
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 18 of 53
Investigator
Program Novartis CLBH589B2203 A Phase II Study of Oral LBH589 in Adult 05/2007 - 04/2009 Director / Patients With Multiple Myeloma.... Funded by Novartis Principal Investigator
Program PX-171-003: An Open-label, Single-arm, Phase 2 Study of Carfilzomib 08/2007 - 08/2009 Director / in Patients with Relapsed and Refractory Multiple Myeloma . Funded by Principal Proteolix, Inc. Investigator
Program Amendment 1 & 2: PX-171-004: Phase 2 Study of Carfilzomib in 10/2007 - 10/2009 Director / Patients with Relapsed Multiple Myeloma: PX-171-004 Amendment 1 & Principal 2: An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients Investigator with Relapsed Multiple Myeloma . Funded by Proteolix, Inc.. (PX-171- 004)
Program CAUY922A2103: Phase I study of AUY922 administered as a single 11/2008 - 11/2011 Director / agent as well as in combination with bortezomib, with or without Principal dexamethasone, in adult patients with relapsed or refractory multiple Investigator myeloma: CAUY922A2103: Phase I-Ib/II study of AUY922 administered as a single agent as well as in combination with bortezomib, with or without dexamethasone, in adult patients with relapsed or refractory multiple myeloma. Funded by Novartis
Program A Phase I Study of the Combination of a Selective Inhibitor of Nuclear 03/2015 - 02/2017 Director / Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Principal Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.: 14- Investigator 008558: A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.. Funded by University of Chicago. (MMRC-0055)
Program ACT - 15-000573 A Phase 2b, Open-Label, Single-Arm Study of 05/2015 - 04/2018 Director / Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Principal Multiple Myeloma Quad-refractory to Previous Therapies: CTA and Investigator Amend#1 CTA 15-000573 ACT A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies. Funded by Karyopharm Therapeutics Inc
Program CTA Amend #1 ARM A - CFZ 1x Weekly dosing: CTA Amend#1 ACT- 06/2015 - 05/2019 Director / 15-001110 A Rand, Open-label, Phase 3 Study in Subjects w Relapsed Principal and Refractory Multiple Myeloma Receiving Carfilzomib in Combination Investigator with Dexamethasone, Comparing Once-weekly versus Twice-weekly Carfilzomib Dosing. Funded by Onyx Therapeutics, Inc.. (CFZ014)
Program CTA Amend#1 ARM B - CFZ 2x Weekly dosing: CTA Amend#1 ACT- 06/2015 - 05/2019 Director / 15-001110 A Rand, Open-label, Phase 3 Study in Subjects w Relapsed Principal and Refractory Multiple Myeloma Receiving Carfilzomib in Combination Investigator with Dexamethasone, Comparing Once-weekly versus Twice-weekly Carfilzomib Dosing. Funded by Onyx Therapeutics, Inc.. (CFZ014)
Program CTA AMend#1 GO29695 / 15-001601: CTA Amend#1 IRB 15-001601 A 07/2015 - 06/2017 Director / PHASE Ib STUDY OF THE SAFETY AND PHARMACOKINETICS OF Principal MPDL3280A (ANTI-PD-L1 ANTIBODY) ALONE OR IN COMBINATION Investigator WITH LENALIDOMIDE IN PATIENTS WITH MULTIPLE MYELOMA
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 19 of 53
(RELAPSED AND POST-AUTOLOGOUS STEM CELL TRANSPLANTATION). Funded by Genentech Incorporated. (GO29695)
Program 16-004843: PHASE 1B/2A OPEN-LABEL, DOSE-ESCALATION 12/2016 - 12/2019 Director / STUDY TO DETERMINE THE MTD, SAFETY AND TOLERABILITY, Principal PHARMACOKINETICS AND PRELIMINARY EFFICACY OF CC-220 Investigator MONOTHERAPY AND IN COMBINATION WITH DEXAMETHASONE IN SUBJECTS WITH REL/REF MM . Funded by Celgene. (CC-220- MM-001)
Co-Investigator An Exploratory Phase II Study of PHA-739358 in Patients with Multiple 05/2008 - 04/2010 Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression. Funded by Nerviano Medical Sciences
Co-Investigator TED10893: A Phase 1 Dose Escalation Safety and Pharmacokinetic 11/2010 - 11/2012 Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies: 10-002922/TED10893: A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies. Funded by Sanofi Aventis. (TED10893)
Mayo Clinic Program A Pilot Study Examining the Utility of Tumor WGS to Find Potential 03/2012 - 02/2017 Director / Targets for Therapy in Patients with Advanced Cancer: A Pilot Study Principal Examining the Utility of Whole Genome Tumor Sequencing (WGS) and Investigator Whole Genome Expression Profile to Find Potential Targets for Therapy in Patients with Advanced Cancer. Funded by Hematology - NP/PA
Completed Grants Federal Program Developmental Funds--Mayo Comprehensive Cancer Center. Funded 03/2007 - 06/2007 Director / by National Cancer Institute. (P30 CA015083-33 STEW) Principal Investigator
Program Developmental Funds--Mayo Comprehensive Cancer Center. Funded 07/2007 - 02/2009 Director / by National Cancer Institute. (P30 CA015083-33 STEW) Principal Investigator
Program The Molecular Basis for Bortezomib Activity. Funded by National 07/2007 - 05/2012 Director / Cancer Institute. (R01 CA129009) Principal Investigator
Program Proteasome-Directed Novel Myeloma Therapies Proj 1: Proteasome- 09/2008 - 08/2013 Director / Directed Novel Myeloma Therapies - Proj 1. Funded by National Cancer Principal Institute. (P50 CA100707-06) Investigator
Program A Genome Wide RNAi Vulnerability Map for Myeloma. Funded by 09/2008 - 07/2013
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 20 of 53
Director / National Cancer Institute. (R01 R01 CA133115-01) Principal Investigator
Project Leader 4. Proj 4 Targeting IMID Resistance in Myeloma: Mayo Clinic Multiple 07/2014 - 06/2019 Myeloma SPORE. Funded by National Cancer Institute. (P50 P50 CA186781)
Co-Investigator Chromosomal Abnormalities in Myeloma as Detected by FISH. Funded 03/2009 - 07/2014 by National Cancer Institute. (R01 R01 CA083724)
Co-Program Phase II Trial of cdk Inhibitor SCH 727965 (NSC 747135) in Multiple 01/2010 - 12/2010 Director / Myeloma . Funded by National Institutes of Health Principal Investigator
Foundation Principal Influence of Growth Factors on Malignant B Cell Contamination of 01/1992 - 01/1994 Investigator Peripheral Blood Stem Cell Collections. Funded by Canadian Red Cross
Principal The Molecular Basis of Pathogenic Autoantibodies. Funded by 01/1993 Investigator University of Toronto Deans Fund
Principal Hematopoietic Stem Cells as Vehicles for Gene Therapy. Funded by 01/1995 - 01/1997 Investigator Canadian Red Cross
Principal A Phase I Clinical Trial of Stem Cell Gene Marking in Multiple Myeloma. 01/1995 - 01/1998 Investigator Funded by Medical Research Council
Principal MDR 1 Gene Transfer in Metastatic Breast Cancer. Funded by National 01/1997 - 01/2000 Investigator Cancer Institute of Canada Breast Cancer Initiative
Principal Cataloguing the Expressed Gene Profile of Multiple Myeloma. Funded 01/2001 - 01/2003 Investigator by Multiple Myeloma Research Foundation
Principal Genetic Immunotherapy of Cancer. Funded by Canadian Institutes for 01/2001 - 01/2005 Investigator Health Research
Principal Developing The Second Generation Myeloma Chip. Funded by 01/2002 - 01/2003 Investigator International Myeloma Foundation Jurior Grant Award
Principal The Role of c-maf in Multiple Myeloma. Funded by Multiple Myeloma 01/2003 - 01/2004 Investigator Research Fellowship Award
Principal The Significance of the Unfolded Protein Response Pathway in Multiple 01/2003 - 01/2004 Investigator Myeloma and it's Potential as a Therapeutic Target. Funded by Multiple Myeloma Research Fellowship Award
Principal Identification of Molecular Targets in Multiple Myeloma. Funded by 01/2003 - 01/2005 Investigator National Cancer Institute of Canada
Principal Molecular Characterization of a Novel Lipase (lpdl) Involved in 01/2003 - 01/2005 Investigator Triglyceride Metabolism. Funded by Canadian Institutes for Health Research
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 21 of 53
Principal Molecular Therapies Targeting B Cell Malignancy. Funded by Canadian 01/2003 - 01/2005 Investigator Institutes for Health Research
Principal Targeting Myeloma Kinases. Funded by Canadian Institutes for Health 01/2004 - 01/2005 Investigator Research
Principal Identification of novel prognostic markers and molecular targets in 01/2005 Investigator myeloma. Funded by Ontario Cancer Research Network
Principal Development of Cyclin D2 Inhibitors for Treatment of Multiple Myeloma. 08/2006 - 08/2008 Investigator Funded by Multiple Myeloma Research Foundation
Program Development of Cyclin D2 Inhibitors for Treatment of Multiple Myeloma. 10/2006 - 09/2010 Director / Funded by The Leukemia & Lymphoma Society. (6066-07) Principal Investigator
Principal Mayo Validation Core Studies of Sunesis Compound. Funded by 07/2007 - 05/2008 Investigator Multiple Myeloma Research Consortium
Principal Validation Core - Pre-clinical Evaluation of SNS-314 in Myeloma. 05/2008 - 04/2009 Investigator Funded by Multiple Myeloma Research Consortium
Program RNAi Identified Co-operating Targets for Myeloma Therapeutics. 10/2008 - 09/2011 Director / Funded by The Leukemia & Lymphoma Society. (6113-09) Principal Investigator
Program Cereblon control of IMiD function. Funded by Multiple Myeloma 08/2011 - 07/2013 Director / Research Foundation Principal Investigator
Program Analysis of Karyopharm Compounds in Myeloma. Funded by Multiple 08/2011 - 08/2013 Director / Myeloma Research Foundation Principal Investigator
Program Development of Novel Therapeutics Targeting High Risk Myeloma. 10/2012 - 09/2015 Director / Funded by The Leukemia & Lymphoma Society. (6372-13) Principal Investigator
Co-Investigator Immunogene Therapy for Acute Leukemia. Funded by Leukemia 01/2000 - 01/2002 Research Fund of Canada
Co-Investigator Gene Terapy of Chronic Lymphocyte Leukemia. Funded by Leukemia 01/2001 - 01/2003 Research Fund of Canada
Co-Investigator Genetic Markers of Outcome in Myeloma. Funded by Leukemia 01/2001 - 01/2003 Research Fund of Canada
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 22 of 53
Co-Investigator Rational Therapeutic Intervention for Myeloma: FGFR3 as a Drug 01/2003 - 01/2005 Target. Funded by Eli Lilly & Co/Charles H. Hollenberg Clinician Scientist Award
Co-Investigator Pre-clinical Studies and Development of a Phase I Study of FGFR3 as a 01/2004 - 01/2005 Drug Target. Funded by Ontario Cancer Research Network
Industry Program Millennium CYBOR-D Phase II Trial of Cyclophosphamide, Bortezomib 10/2006 - 09/2008 Director / and Dexamethasone in Newly Diagonose Symptomatic Multiple Principal Myeloma. Funded by Millennium Pharmaceuticals, Inc. Investigator
Program TAK-901 101: Phase 1 Study of TAK-901 in Subjects With Advanced 12/2008 - 12/2010 Director / Hematologic Malignancies: A Phase 1 Dose Escalation Study of TAK- Principal 901 in Subjects With Advanced Hematologic Malignancies. Funded by Investigator Millennium: The Takeda Oncology Company
Program A Phase Ib multicenter dose-determination study, with an adaptive, 04/2009 - 04/2011 Director / randomized, placebo-controlled, double-blind phase II, using various Principal repeated IV doses of BHQ880 in combination with zoledronic acid in Investigator relapsed or refractory myeloma patients. Funded by Novartis. (CBHQ880A2102)
Program Combined MCA/MCR/MMRC: Phase I/II Study of combination of Aurora 12/2009 - 12/2012 Director / Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Principal Multiple Myeloma: Phase I/II Study of combination of Aurora Kinase Investigator Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc.. (MC088A)
Program CTK1258A2204: A phase II, multi-center, non-randomized, open-label 02/2010 - 02/2012 Director / study of TK1258 in patients with relapsed or refractory multiple Principal myeloma, who are with or without (t(4;14) translocation. Funded by Investigator Novartis. (CTK1258A 2204)
Program MCA 1314-10: EARLY PRECLINICAL EVALUATION OF VORELOXIN 10/2010 - 11/2010 Director / IN MULTIPLE MYELOMA. Funded by Sunesis Pharmaceuticals, Inc. Principal Investigator
Program 10-002630/PX-171-009: A Randomized, Multicenter, Phase 3 Study 11/2010 - 11/2013 Director / Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Principal Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Investigator Multiple Myeloma: 10-002630/ PX-171-009: A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multipl. Funded by Onyx Pharmaceuticals Corporation. (PX-171-009)
Program 10-004943/ An Open-Label, Dose-Escalation Phase 1/2 Study of the 12/2010 - 12/2013 Director / Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, Principal Administered in Combination with Lenalidomide and Low-Dose Investigator Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Req: 10-004943/ C16005/ An Open-Label, Dose-Escalation Phase 1/2
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 23 of 53
Study of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, Administered in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Newly Diagnosed Multiple My. Funded by Millennium Pharmaceuticals, Inc.
Program FRF4998g: OPEN-LABEL PHASE I TRIAL OF ESCALATING DOSES 01/2012 - 01/2015 Director / OF DFRF4539A IN PTS W/RELAPSED OR REFRACTORY MULTIPLE Principal MYELOMA: 11-004729/FRF4998g: AN OPEN-LABEL, MULTICENTER, Investigator PHASE I TRIAL OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF DFRF4539A IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA. Funded by Genentech Incorporated. (FRF 4998g)
Program 11-005475 Replacement Budget/ PKB115125/ A Phase Ib Study to 04/2012 - 03/2013 Director / Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Principal of the Oral AKT Inhibitor GSK2110183 Administered in Combination Investigator with Bortezomib and Dexamethasone in Subjects with Relapsed: 11- 005475 Replacement Budget/ PKB115125/ A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 Administered in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed/. Funded by GlaxoSmithKline. (PKB115125)
Program 11-006968: 2011-002: MCA: Carfilzomib Multiple Myeloma Expanded 06/2012 - 06/2014 Director / Access Protocol for Patients with Relapsed and Refractory Disease: 11- Principal 006968: 2011-002: Carfilzomib Multiple Myeloma Expanded Access Investigator Protocol for Patients with Relapsed and Refractory Disease. Funded by Onyx Pharmaceuticals Corporation
Program CX-839-002 Lymphoma including WM: 14-000452 - A Phase 1 Study of 05/2014 - 04/2016 Director / the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Principal Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Investigator Advanced and/or Treatment-Refractory Hematological Malignancies. Funded by Calithera Biosciences
Program CX-839-002 Lymphoma including WM: 14-000452 - CONTRACT 05/2014 - 04/2016 Director / AMENDMENT 1: A Phase 1 Study of the Safety, Pharmacokinetics, and Principal Pharmacodynamics of Escalating Oral Doses of the Glutaminase Investigator Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies. Funded by Calithera Biosciences
Program CX-839-002 Lymphoma including WM: 14-000452 - CONTRACT 05/2014 - 04/2016 Director / AMENDMENT 2: A Phase 1 Study of the Safety, Pharmacokinetics, and Principal Pharmacodynamics of Escalating Oral Doses of the Glutaminase Investigator Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies. Funded by Calithera Biosciences
Program CX-839-002 Multiple Myeloma Combo with CBD and CBPD: 14-000452 05/2014 - 04/2016 Director / - CONTRACT AMENDMENT 1: A Phase 1 Study of the Safety, Principal Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of Investigator the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies. Funded by Calithera Biosciences
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 24 of 53
Program CX-839-002 Multiple Myeloma Combo with CBD and CBPD: 14-000452 05/2014 - 04/2016 Director / - CONTRACT AMENDMENT 2: A Phase 1 Study of the Safety, Principal Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of Investigator the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies. Funded by Calithera Biosciences
Program CX-839-002 Multiple Myeloma: 14-000452 - A Phase 1 Study of the 05/2014 - 04/2016 Director / Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Principal Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced Investigator and/or Treatment-Refractory Hematological Malignancies. Funded by Calithera Biosciences
Program CX-839-002 Multiple Myeloma: 14-000452 - CONTRACT 05/2014 - 04/2016 Director / AMENDMENT 1: A Phase 1 Study of the Safety, Pharmacokinetics, and Principal Pharmacodynamics of Escalating Oral Doses of the Glutaminase Investigator Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies. Funded by Calithera Biosciences
Program CX-839-002 Multiple Myeloma: 14-000452 - CONTRACT 05/2014 - 04/2016 Director / AMENDMENT 2: A Phase 1 Study of the Safety, Pharmacokinetics, and Principal Pharmacodynamics of Escalating Oral Doses of the Glutaminase Investigator Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Hematological Malignancies. Funded by Calithera Biosciences
Co-Investigator 08-001584: MC0882: A Phase 2 Study of Lenalidomide (Revlimid), 05/2008 - 05/2013 Rituximab, Cyclophosphamide and Dexamethasone (R2-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Treatment: 08-001485: MC0882: A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) for Untreated Low Grade Non-Hodgkin Lymphoma Requiring Treatment. Funded by Celgene
Co-Program CA180180: A Phase I Single Arm Dose Escalation Study of the 06/2008 - 06/2011 Director / Combination of Dasatinib (Sprycel) with Lenalidomide (Revlimid) and Principal Dexamethasone in Subjects with Relapsed and/ or Refractory Multiple Investigator Myeloma: CA180180: A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel®) with Lenalidomide (Revlimid®) and Dexamethasone in Subjects with Relapsed and/ or Refractory Multiple Myeloma. Funded by Bristol-Myers Squibb Pharmaceutical
Co-Investigator MC0883: Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and 10/2008 - 10/2013 Dexamethasone (R-CyBor-D) in Lymphoma: MC0883: A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE®), and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma. Funded by Millennium
Co-Investigator A PHASE 1/2 OF CC-4047 ALONE OR IN COMBO 11/2009 - 11/2014 W/DEXAMETHASONE IN PTS W/RELAPSED AND REFRACOTRY MM: CC-4047-MM-002: A Phase 1/2 Multi-center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of CC-4047 Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refracotory . Funded by Celgene. (CC-4047-MM-002)
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 25 of 53
Co-Investigator C16004: An Open-Label, Dose-Escalation, Phase 1 Study Evaluating 09/2010 - 09/2012 the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Relapsed and Refractory Multiple Myeloma. Funded by Millennium Pharmaceuticals, Inc.
Co-Investigator 10-007931/C18770/2043: PHASE 2: An Open-Label Study to 10/2010 - 10/2012 Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients with Relapsed Multiple Myeloma Refractory to the Most Recent Therapy: C18770/2043: An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients with Relapsed Multiple Myeloma Refractory to the Most Recent Therapy. Funded by Cephalon, Incorporated. (C18770/2043)
Co-Investigator DO NOT USE: C18770/2043: PHASE 1: An Open-Label Study to 10/2010 - 10/2012 Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients with Relapsed Multiple Myeloma Refractory to the Most Recent Therapy: C18770/2043: An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients with Relapsed Multiple Myeloma Refractory to the Most Recent Therapy. Funded by Cephalon, Incorporated. (C18770/2043)
Mayo Clinic Principal High Throughput Exon-Scanning of the Kinome in Multiple Myeloma. 01/2004 - 01/2005 Investigator Funded by Multiple Myeloma Research Foundation
Principal AMD3100-CUP001-Compassionate Protocol for the Use of AMD3100 to 10/2007 - 09/2009 Investigator Mobilize Peripheral Blood Stem Cells for Collection and Transplantation. Funded by Mayo Protocol
Co-Program Comprehensive genetic profiling of multiple myeloma for prognosis and 03/2014 - 08/2015 Director / disease monitoring. Funded by CIM - Center for Individualized Medicine Principal Investigator
Patents Title Patent Number Date Filed Date Issued Clioquinol for the Treatment of Hematological US 123617 01/2011 01/2011 Malignancies: Serial No: US60/980, 783 Inventors: Schimmer AD, Mao X, Stewart AK
Effects of Inhibitors of FGFR3 on Gene US 149714 06/2008 01/2012 Transcription Inventors: Heise C, Mashih-Khan E, Moler E, Rowe R, Stewart K, Trudel S
Other Patents Tiedemann RE, Stewart AK. Inhibiting Cyclin D Gene Expression and Polypeptide
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 26 of 53
Activity. Provisional application number 60/850,567; filed October 10, 2006; converted PCT application number PCT/US2007/080978; filed October 10, 2007; Publication number W02008/045955; national phase. U.S. national application number 12/445,065; filed February 15, 2010; Publication number US2010/0144685; pending. Canada national application number 2,673,489; filed October 10, 2007; pending.
Schimmer AD, Mao X, Stewart AK. Clioquinol for the Treatment of Hematological Malignancies: Serial No: US60/980, 783; filed October 18, 2007, TDC reference number: 2007- 009. PCT application number PCT/CA2008/001812; filed October 16, 2008; publication number WO2009/049410; national phase. U.S. national application number 12/738,388; filed January 15, 2011; publication number US2011/0123617.
Heise C, Mashih-Khan E, Moler E, Rowe R, Stewart K, Trudel S. Case No: 52020 Patent Application in the name of Novartis AG entitled: Effects of Inhibitors of FGFR3 on Gene Transcription, May 2008. WO 2007/067968 A2. PCT/US2006/061766. Provisional application number 60/748,944; filed December 8, 2005; converted. PCT application number PCT/US2006/061766; filed December 7, 2006; publication number WO2007/067968 national phase. U.S. national application number 12/096,222; filed June 19, 2008; publication number US2009/0048266; issued on April 17, 2012; patent number US8,158,360. U.S. national application number 13/400,833; filed February 21, 2012; publication number US2012/0149714.
Stewart, AK, Braggio E, Bergsagel PL, Fonseca R. Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs. Provisional application number 61/452,027; filed March 11, 2011; converted. PCT application number PCT/US2012/028285; filed March 8, 2012; Publication number WO2012/125405; pending.
Stewart, AK. Inhibiting G Protein Coupled Receptor 6 Kinase Polypeptides. Provisional application number 61/552,015; filed October 27, 2011; converted PCT application number PCT/US2012/062206; filed October 26, 2012; pending.
Fonseca, R, Stewart, AK, Bergsagel PL, Chesi, M. Treating Multiple Myeloma. Provisional application number 61/426,698; filed December 23, 2010; converted. PCT application number PCT/US2011/066772; filed December 22, 2011; national phase. U.S. national application number 13/995,623. Filing date 6/19/2013.
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 27 of 53
Bibliography
Peer-reviewed Articles 1. Stewart AK, Keating A. Acute leukaemia-diagnosis, management and potential for cure. Can Fam Phys. 1988; 34:2463-7.
2. Stewart AK, Glynn MF. Acquired von Willebrand disease associated with free lambda light chain monoclonal gammopathy, normal bleeding time and response to prednisone. Postgrad Med. 1990; 66:560-2.
3. Stewart AK, Freedman J, Garvey MB. Acute leukaemia evolving from multiple myeloma and co-expressing myeloid and plasma cell antigens. Am J Hematol. 1990; 34(3):210-4. PMID:2363415
4. Stewart AK, Keating A, Sutton D, Scott JG, Carter WH, Francombe W, Baker MA. Adult acute lymphoblastic leukaemia:th value of therapy intensification. Leuk Lymphoma. 1990; 4:130-10.
5. Stewart AK, Carstairs KC, Dube ID, Keating A. Neurtrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia. Am J Hematol. 1990; 34:59-63. PMID:2327406
6. Stewart AK, Shepherd FA, Goss PE, Warner E, Bailey DJ, Baker MA. Gastrointestinal non-Hodgkin's lymphoma. Leuk Lymphoma. 1991; 4:167-76.
7. Stewart AK, Brandwein J, Sutcliffe S, Scott JG, Keating A. Mini-BEAM salvage chemotherapy for refractory Hodgkin's disease and non-Hodgkin's lymphoma. Leukemia and Lymphoma. 1991; 5:111-5.
8. Stewart AK, Schuh AC, Keating A. T-cell blast crisis in chronic myeloid leukemia. Leuk Lymphoma. 1991; 3(2):319-24.
9. Huang C, Stewart AK, Schwartz, RS, Stollar BD. Immunoglobulin heavy chain gene expression in peripheral blood B lymphocytes. J Clin Invest. 1992; 89:1331-43. PMID:1556192 PMCID:442995
10. Feedman J, Semple J, Teitel J, Stewart AK, Guillaume T. Immunologic dysfunction induced by staphylococcal protein A immunoabsorption. Transfusion Science. 1992; 13:223-32.
11. Stewart AK, Huang C, Long AA, Stollar BD, Schwartz RS. VH-gene representation in autoantibodies reflects the normal human B-cell repoertoire. Immunol Rev. 1992; 128:101-22. PMID:1427920
12. Sutherland DR, Stewart AK, Keating A. CD34 antigen: molecular features and potential clinical applications. Stem Cells. 1993; 11(Suppl 3):50-7. PMID:7507757
13. Carere R, Stewart AK, Bailey D, Baker MA. Extensive cutaneous plasmacytoma. Leuk Lymphoma. 1993; 10:493-5. PMID:8401186
14. Stewart AK, Huang C, Stollar BD, Schwartz RS. High frequency representation of a single VH gene in the expressed human B cell repertoire. J Exp Med. 1993; 177:409-18. PMID:8426111 PMCID:2190904
15. Rubinstein DB, Symann M, Stewart AK, Guillaume T. Restriction fragment length polymorphisms and single germline coding region sequence in VH18/2, a duplicated gene encoding autoantibody. Mol Immunol. 1993; 30:403-12. PMID:8096063
16. Rubinstein DB, Schwartz RS, Guillaume T, Leblanc P, Stewart AK. Germline complexity restriction fragment length polymorphism and coding region sequences of the human VH7 gene family identified with family- specific FR3 segment oligonucleotides. Mol Immunol. 1994; 31:713-21. PMID:7913518
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 28 of 53
17. Sutherland DR, Keating A, Nayar R, Anania S, Stewart AK. Sensitive detection and enumeration of CD34+ cells in peripheral and cord blood by flow cytometry. Exp Hematol. 1994; 22:1003-10. PMID:7522181
18. Stewart AK, Schwartz RS. Immunoglobulin V regions and the B cell. Blood. 1994 Apr 1; 83(7):1717-30. PMID:8142639
19. Dube I, Stewart AK, Lutzko C, Kruth S, Abrams-Ogg A, Schull R, Danos O, Kohn D, Reddy V, Chu P, Kamel- Reid S. Gene transfer into marrow-derived hematopoietic stem cells. Gene Ther. 1995; 2:579-80.
20. Prince HM, Page SR, Keating A, Saragosa RF, Vukovic NM, Imrie KR, Crump M, Stewart AK. Microbial contamination of harvested bone marrow and peripheral blood. Bone Marrow Transplant. 1995 Jan; 15(1):87- 91. PMID:7742761
21. Colwill R, Crump M, Couture F, Stewart AK, Sutton DM, Scott JG, Sutcliffe S, Brandwein JM, Keating A. Mini- BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol. 1995; 13:369-402. PMID:7844600
22. Stewart AK, Dube ID. Monitoring cancer relapse with retroviral gene marked autologous blood or bone marrow cells; What have we learned and what next? (Invited Review). Gene Ther. 1995; 2:590-1. PMID:7584111
23. Stewart AK, Imrie K, Keating A, Anania S, Nayar R, Sutherland DR. Optimizing the CD34+ and CD34+Thy-1+ stem cell content of peripheral blood collections. Exp Hematol. 1995; 23:1619-27. PMID:8542956
24. Dube ID, Stewart AK. Adoptive transfer of genetically modified hematopoietic stem cells (Invited Review). Transfusion Science. 1996; 17(1):137-47.
25. Stewart AK, Prince HM, Dube ID. Background and update to phase I trial of stem cell gene marking in multiple myeloma (Invited Review). Transfusion Science. 1996; 17:175-84.
26. Imrie K, Stewart AK, Crump RM, Prince HM, Trip K, Keating A. Blood stem cell collection: factors influencing the recovery of granulocyte-macrophage colony forming cells. Cell Transplant. 1996; 5(3):379-83. PMID:8727006
27. Stewart AK. Gene marking and cancer relapse - what have we learned and what next? (Invited Review). Gene Delivery System - A State of the Art Review, OECD Publications. 1996:253-64.
28. Sutherland DR, Yeo EL, Stewart AK, Nayar R, DiGiusto R, Zanjani E, Hoffman R, Murray LJ. Identification of CD34+ subsets after glycoprotease selection: engraftment of CD34+Thy-1+Lin- stem cells in fetal sheep. Exp Hematol. 1996; 24(7):795-806. PMID:8647230
29. Prince HM, Crump M, Imrie K, Stewart AK, Girouard C, Brandwein JM, Carstairs K, Pantalony D, Scott G, Sutcliffe S, Sutton DM, Tsang R, Keating A. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Ann Oncol. 1996; 7:1043-9. PMID:9037363
30. Prince HM, Imrie K, Keating A, Merharchand J, Crump MR, Girouard C, Trip K, Stewart AK. Peripheral blood progenitor cell collections in multiple myeloma; predictors and management of inadequate collections. British J of Hematol. 1996; 93(1):142-5.
31. Dube ID, Kurth S, Abrams-Ogg A, Kamel-Reid S, Lutzko C, Nanji S, Ruedy C, Singaraja R, Wild A, Krygsman P, Chu P, Messner H, Reddy V, McGarrity G, Stewart AK. Preclinical assessment of human hematopoietic progenitor cell transduction in long-term marrow cultures. Hum Gene Ther. 1996; 7:2089-100. PMID:8934223
32. Prince HM, Imrie K, Crump M, Stewart AK, Girouard C, Colwill R, Brandwein J, Tsang RW, Scott JG, Sutton DM, Pantalony D, Carstairs K, Sutcliffe SB, Keating A. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br J Haematol. 1996; 92(4):882-9. PMID:8616081
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 29 of 53
33. Imrie K, Sheridan B, Colwill R, Crump M, Stewart AK, McCrae J, Danish R, Sutton D, Romeyer F, Keating A. A phase I study of interleukin-6 after autologous bone marrow transplantation for patients with poor prognosis Hodgkin's disease. Leuk Lymphoma. 1997; 25:555-63. PMID:9250827
34. Couban S, Stewart AK, Loach D, Panzarella T, Meharchand J. Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant. 1997; 19:783-9. PMID:9134169
35. al-Fiar F, Prince HM, Imrie K, Stewart AK, Crump M, Keating A. Bone marrow mononuclear cell count does not predict neutrophil and platelet recovery following autologous bone marrow transplant: value of the colony- forming unit granulocyte-macrophage (CFU-GM) assay. Cell Transplant. 1997; 6(5):491-5. PMID:9331500
36. Stewart AK, Prince HM, Cappe D, Chu P, Lutzko C, Sutherland DR, Dube ID. In vitro maintenance and retroviral transduction of human myeloma cells in long-term marrow cultures. Cancer Gene Ther. 1997; 4(3):148-56. PMID:9171933
37. Girouard C, Dufresne J, Imrie K, Stewart AK, Brandwein J, Prince HM, Pantolony D, Keating A, Crump M. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol. 1997; 8:675-80. PMID:9296221
38. Stelfox HT, Stewart AK, Bailey D, Harrison D. Castleman's disease in a 44-year-old male with neurofibromatosis and pheochromocytoma. Leuk Lymphoma. 1997 Nov; 27(5-6):551-6. PMID:9477139
39. Catzavelos C, Ruedy C, Stewart AK, Dube I. A novel method for the direct quantification of gene transfer into cells using PCR in situ. Gene Ther. 1998; 5:755-60. PMID:9747455
40. Prince HM, Dessureault S, Gallinger S, Krajden M, Sutherland DR, Addison C, Zhang Y, Graham FL, Stewart AK. Efficient adenovirus-mediated gene expression in malignant human plasma cells: relative lymphoid cell resistance. Exp Hematol. 1998; 26(1):27-36. PMID:9430511
41. Claudio JO, Liew CC, Dempsey AA, Cukerman E, Stewart AK, Na E, Atkins HL, Iscove NN, Hawley RG. Identification of sequence-tagged transcripts differentially expressed within the human hematopoietic hierarchy. Genomics. 1998; 50(1):44-52. PMID:9628821
42. Schimmer AD, Quatermain M, Imrie K, Ali V, McCrae J, Stewart AK, Crump M, Derzko C, Keating A. Ovarian function after autologous bone marrow transplantation . J Clin Oncol. 1998; 16(7):2359-63. PMID:9667251
43. Chu P, Lutzko C, Stewart AK, Dube ID. Retrovirus-mediated gene transfer into human hematopoietic stem cells (Invited Review). J Mol Med. 1998; 76:184-92. PMID:9535551
44. Schimmer AD, Stewart AK, Keating A, MacKinnon J, Crump M, Sutton DM, Shepherd FA, Meharchand J. Safety of therapeutic anticoagulation in patients with multiple myeloma receiving autologous stem cell transplantation. Bone Marrow Transplant. 1998; 22(5):491-4. PMID:9733273
45. Kahr WH, Al-Homadhi A, Meharchand J, Bailey DJ, Stewart AK. Testicular plasmacytoma following chemical orchiectomy: potential role of hypogonadism in myeloma proliferation. Leuk Lymphoma. 1998; 28:437-42. PMID:9517517
46. Stewart AK, Schimmer AD, Bailey DJ, Dube ID, Cappe D, Moen RC, Gauldie J, Graham FL. In vivo adenoviral mediated gene transfer of Interleukin 2 in cutaneous plasmacytoma. Blood. 1998 Feb; 91(3):1095-7. PMID:9446678
47. Tisdale JF, Stewart AK, Dickstein B, Little RF, Dube I, Cappe D, Dunbar CE, Brown KE. Molecular and serological examination of the relationship of human herpesvirus 8 to multiple myeloma: orf 26 sequences in bone marrow stroma are not restricted to myeloma patients and other regions of the genome are not detected. Blood. 1998 Oct; 92(8):2681-7. PMID:9763550
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 30 of 53
48. Donohue JH, Stewart AK, Menck HR. The National Cancer Data Base report on carcinoma of the gallbladder, 1989-1995. Cancer. 1998 Dec 15; 83(12):2618-28. PMID:9874470
49. Stewart AK, Gauldi J, Krajeden M, Bailey D, Rotstein L, Cappe D, Addison CL, Moen RC, Lassam N, Graham FL. Adenovector mediated gene delivery of Interleukin 2 in metastatic breast cancer and melanoma: results of phase 1 clinical trial. Gene Ther. 1999; 6(3):350-63. PMID:10435085
50. Omori F, Lutzko C, Abrams-Ogg A, Lau K, Gartley C, Dobson H, Nanji S, Ruedy C, Singaraja R, Li L, Stewart AK, Kruth S, Dube ID. Adoptive transfer of genetically modified human hematopoietic stem cells into preimmune canine fetuses. Exp Hematol. 1999; 27:242-9. PMID:10029163
51. Claudio JO, Liew CC, Ma J, Heng HH, Stewart AK, Hawley RG. Cloning and expression analysis of a novel WD repeat gene, WDR3, mapping to 1p12-p13. Genomics. 1999; 59:85-9. PMID:10395803
52. Krieger MS, Schiller G, Berenson JR, Stewart AK, Noga SJ, Ballester O, Tarantolo S, Stiff P, Kuhn D, Scherzo E, Jacobs C, White JM, DiPersio J. Collection of peripheral blood progenitor cells (PBPC) based on a rising WBC and platelet count significantly increase the number of CD34+ cells. Bone Marrow Transplant. 1999; 24(1):25-8. PMID:10435730
53. Goss P, Stewart AK, Couture F, Klasa R, Gluck R, Kaizer L, Burkes R, Charpentier D, Palmer M, Tye L, Dulude H. Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas. Leuk Lymphoma. 1999; 34(3-4):295-304. PMID:10439366
54. Stewart AK, Gupta H, Cappe D, Sutherland DR. Erythropoiesis: splenic immunoglobulin variable region genes encoding red blood cell binding FAB fragments in autoimmune hemolytic anemia. Hematol. 1999; 4:165-78. PMID:11399561
55. Chang H, Bouman D, Boerkoel CF, Stewart AK, Squire JA. Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia. 1999 Jan; 13(1):105-9. PMID:10049044
56. Howard DS, Rizzieri DA, Grimes B, Upchurch D, Phillips G, Stewart AK, Yanelli JR, Jordan CT. Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediate a gene transfer. Leukemia. 1999; 13:1608-16. PMID:10516763
57. Saba N, Sutton D, Ross H, Siu S, Crump R, Keating A, Stewart AK. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant . Bone Marrow Transplant. 1999; 8:853-5.
58. Abraham R, Chen C, Tsang R, Simpson D, Murray D, Davidson M, Meharchand J, Sutton DM, Crump RM, Keating A, Stewart AK. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Bone Marrow Transplant. 1999; 12:1291-7.
59. Stewart AK, Trudel S, Al-Berouti BM, Sutton DM, Meharchand J. Lack of response to short-term use of clarithromycin (BIAXIN™)in multiple myeloma. Blood. 1999; 83:4441.
60. Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, DiPersio J, Anderson K, Berenson J. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999; 93(6):1858-68. PMID:10068658
61. Crump M, Lipton J, Hedley D, Sutton D, Shepherd F, Minden M, Stewart AK, Beare S, Eisenhauer E. Phase 1 trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: A National Cancer Institute of Canada Clinical Trials Group Study. Leukemia. 1999; 13(3):343-7. PMID:10086724
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 31 of 53
62. Lutzko C, Dube ID, Stewart AK. Recent progress in gene transfer into hematopoietic stem cells. Crit Rev Oncol Hematol. 1999; 30:143-58. PMID:10439059
63. Omori F, Juopperi T, Chan CK, Chan YN, Phipps S, Nanji S, Zhao Y, Stewart AK, Dube ID. Retroviral- mediated transfer and expression of the multidrug resistance protein 1 gene (MRP1) protects human hematopoietic cells from antineoplastic drugs. J Hematother Stem Cell Res. 1999; 8(5):503-14. PMID:10791901
64. LaCasse EC, Bray MR, Patterson B, Lim WM, Perampalam S, Radvanyi LG, Keating A, Stewart AK, Buckstein R, Sandhu JS, Miller N, Banerjee D, Singh D, Belch AR, Pilarski LM, Gariepy J. Shiga-like toxin-1 receptor on human breast cancer, lymphoma and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem celll transplantation. Blood. 1999; 94:2901- 10. PMID:10515895
65. Wen XY, Stewart AK, Sooknanan RR, Henderson G, Hawley TS, Reimold AM, Glimcher LH, Baumann H, Malek LT, Hawley RG. Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells. Int J Oncol. 1999 Jul; 15(1):173-8. PMID:10375612
66. Stewart AK, Sutherland DR, Nanji S, Zhao Y, Lutzko C, Nayar R, Peck B, Ruedy C, McGarrity G, Tisdale J, Dube ID. Engraftment of gene-marked hematopoietic progenitors in myeloma patients after transplant of autologous long-term marrow cultures. Hum Gene Ther. 1999 Aug; 10(12):1953-64. PMID:10466629
67. Stewart AK, Schuh A. Advances in understanding the molecular basis of hematologic malignancies and their impact on clinical practice (Invited Review). Lancet. 2000; 355:1447-54. PMID:10791539
68. Dilworth D, Liu L, Stewart AK, Berenson JR, Lassam N, Hogg D. Germline CDKN2A mutation implicated in predisposition to multiple myeloma. Blood. 2000; 95(5):1869-71. PMID:10688850
69. Vescio RA, Wu CH, Zheng L, Sheen D, Ma H, Liu J, Stewart AK, Ballester O, Noga SJ, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Schiller GJ, White M, Jacobs C, DiPersio J, Anderson KC, Berenson JR. Human herpesvirus 8 (KSHV) contamination of the peripheral blood and autograft products of multiple myeloma patients. Bone Marrow Transplant. 2000; 25(2):153-60. PMID:10673673
70. Patnaik A, MacKinnon J, Goss P, Nagy T, Stewart AK, Keating A, Crump M. Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer. J Clin Oncol. 2000; 18(12):2363. PMID:10856095
71. * Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG, Stewart AK. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. Blood. 2000 Feb 1; 95(3):992-8. PMID:10648414
72. Chen CI, Crump M, Tsang R, Stewart AK, Keating A. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. B J Haematol. 2001; 113(1):202-8.
73. Schimmer AD, Ali V, Stewart AK, Imrie K, Keating A. Male sexual function after autologous blood or marrow transplantation. Biol Blood Marrow Transplant. 2001; 7(5):279-83. PMID:11400950 DOI:10.1053/bbmt.2001.v7.pm11400950
74. Chen CI, Abraham R, Tsang R, Crump M, Keating A, Stewart AK. Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes. Bone Marrow Transplant. 2001 Jan; 27(2):177-82. PMID:11281387 DOI:10.1038/sj.bmt.1702771
75. Wen XY, Stewart AK, Skaug J, Wei E, Tsui LC. Murine phosphatidylserine-specific phospholipase A1 (Ps- pla1) maps to chromosome 16 but is distinct from the lpd (lipid defect) locus. Mamm Genome. 2001 Feb; 12(2):129-32. PMID:11210182
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 32 of 53
76. Wen XY, Bai Y, Stewart AK. Adenovirus-mediated human endostatin gene delivery demonstrates strain- specific antitumor activity and acute dose-dependent toxicity in mice. Hum Gene Ther. 2001 Mar 1; 12(4):347- 58. PMID:11242527 DOI:10.1089/10430340150503975
77. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommoss F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C, Rochlitz C. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small- cell lung cancer: results of a multicenter phase II study. J Clin Oncol. 2001 Mar 15; 19(6):1750-8. PMID:11251006
78. * Li Z, Zhu YX, Plowright EE, Bergsagel PL, Chesi M, Patterson B, Hawley TS, Hawley RG, Stewart AK. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood. 2001 Apr 15; 97(8):2413-9. PMID:0
79. Trudel S, Li Z, Dodgson C, Nanji S, Wan Y, Voralia M, Hitt M, Gauldie J, Graham FL, Stewart AK. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma--a phase 1 study. Leukemia. 2001 May; 15(5):846-54. PMID:11368448
80. Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Stewart AK. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001 May 1; 50(1):113-20. PMID:11316553
81. Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS, Hawley RG, Stewart AK. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther. 2001 May; 8(5):361-70. PMID:11477456 DOI:10.1038/sj.cgt.7700321
82. Claudio JO, Zhu YX, Benn SJ, Shukla AH, McGlade CJ, Falcioni N, Stewart AK. HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells. Oncogene. 2001 Aug 30; 20(38):5373-7. PMID:11536050 DOI:10.1038/sj.onc.1204698
83. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, Freytes C, Stadtmauer E, Tarantolo S, Sahebi F, Stiff P, Meharchard J, Schlossman R, Brown R, Tully H, Benyunes M, Jacobs C, Berenson R, White M, DiPersio J, Anderson KC, Berenson J. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol. 2001 Sep 1; 19(17):3771-9. PMID:11533101
84. Claudio JO, Masih-Khan E, Tang H, Goncalves J, Voralia M, Li ZH, Nadeem V, Cukerman E, Francisco- Pabalan O, Liew CC, Woodgett JR, Stewart AK. A molecular compendium of genes expressed in multiple myeloma. Blood. 2002; 100(6):2175-86. PMID:12200383
85. Zhu YX, Li ZH, Voralia M, Stewart AK. Antigenic open reading frames from HHV-8 are present in multiple myeloma patients and normal individuals at similar frequency. Leuk Lymphoma. 2002; 43(2):369-75. PMID:11999572
86. Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood. 2002; 100(10):3819-21. PMID:12393593
87. Wang J, Wen XY, Stewart AK, Hegele RA. Polymorphisms in the gene encoding phosphatidylserine-specific phospholipase A1(PSPLA1). J Hum Genet. 2002; 47(11):611-13. PMID:12436198
88. Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 2002; 30(12):885-91. PMID:12476281
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 33 of 53
89. Chin-Yee IH, Keeney M, Stewart AK, Belch A, Bence-Buckler I, Couban S, Howson-Jan K, Rubinger M, Stewart D, Sutherland R, Paragamian V, Bhatia M, Foley R. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets. Bone Marrow Transplant. 2002 Dec; 30(12):851- 60. PMID:12476276
90. Wen XY, Hegele RA, Wang J, Wang DY, Cheung J, Wilson M, Yahyapour M, Bai Y, Zhuang L, Skaug J, Young TK, Connelly PW, Koop BF, Tsui LC, Stewart AK. Identification of a novel lipase gene mutated in lpd mice with hypertriglyceridemia and associated with dyslipidemia in humans. Hum Mol Genet. 2003; 12(10):1131-43. PMID:12719377
91. Li ZH, Wen XY, Mandelbaum S, Falcioni N, Hawley TS, Hawley RG, Stewart AK. Improved therapeutic outcome following combination immunogene vaccination therapy in murine myeloma. Leuk Lymphoma. 2003; 44(10):1775-84. PMID:14692533
92. Wechalekar AD, Chen CI, Sutton D, Reece D, Voralia M, Stewart AK. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Leuk Lymphoma. 2003; 44(7):1147-9. PMID:12916866
93. Onwuazor ON, Wen XY, Wang DY, Zhuang L, Masih-Khan E, Claudio J, Barlogie B, Shaughnessy JD Jr, Stewart AK. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood. 2003; 102(2):772-3. PMID:12835230
94. Cheon, MS, Bajo M, Kim SH, Claudio JO, Stewart AK, Patterson D, Kruger WD, Kondoh H, Lubec G. Protein levels of genes encoded on chromosome 21 in fetal Down syndrome brain: challenging the gene dosage effect hypothesis (Part II). Amino Acids. 2003; 24(1-2):119-25. PMID:12624743
95. Pollett JB, Zhu YX, Gandhi S, Bali M, Masih-Khan E, Li Z, Wen XY, Stewart AK. RU486-inducible retrovirus- mediated caspase-3 overexpression is cytotoxic to bcl-xL-expressing myeloma cells in vitro and in vivo. Mol Ther. 2003; 8(2):230-7. PMID:12907145
96. Anderson KC, Barlogie B, Berenson JR, Dalton WS, Adams J, Alsina M, Bekker P, Bergsagel PL, Boise L, Chan K, Chanan-Khan AA, Comenzo R, Congdon D, Croucher P, Epstein J, Fenton R, Fonseca R, Gallant G, Hussein MA, Janannath S, Pearse RN, Goodman DG, Sausville E, Shaughnessy JD, Stewart AK, Stirling DI, Trudel S, Vanness B, Witzig TE. The development of novel targeted therapeutics for treatment of multiple myeloma research roundtable. Eur J Haematol. 2003; 70:263-72.
97. Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y, Gauldie J, Graham FL, Dancey J, Stewart AK. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Thery. 2003 Oct; 10(10):755-63.
98. Chag H, Samiee S, Li D, Patterson B, Chen CI, Stewart AK. Analysis of IgH translocations, chromosome 13q14 and 17p13.1 (p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single centre study of 22 cases. Leukemia. 2004; 18(6):1160-2. PMID:15103388
99. Mollee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C, Stewart AK. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant. 2004; 33(3):271-7. PMID:14647248
100. Chang H, Li D, Zhuang L, Nie E, Bouman D, Stewart AK, Chun K. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma. 2004; 45:965-9. PMID:15291356
101. Claudio JO, Masih-Khan E, Stewart AK. Insights from the gene expression profiling of multiple myeloma. Curr Hematol Rep. 2004; 3(1):67-73. PMID:14695854
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 34 of 53
102. Paterson JL, Li Z, Wen XY, Masih-Khan E, Chang H, Reece D, Pollett J, Trudel S, Stewart AK. Pre-clinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. B J Haematol. 2004; 124(5):595-603. PMID:0
103. Stewart AK, Chen CI, Howson-Jan K, White D, Roy J, Kovacs MJ, Shustik C, Sadura A, Shepherd L, Ding K, Meyer RM, Belch AR. Results of a multicentrer randomized phase II trial of thalidomide nd prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res. 2004; 10:8170-6. PMID:15623591
104. Trieu Y, Wen XY, Skinnider BF, Bray MR, Li Z, Claudio J, Masih-Khan E, Zhu YX, Trudel S, McCart JA, Mak TW, Stewart AK. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin's lymphoma growth in vitro and in vivo. Cancer Res. 2004; 74:3271-5. PMID:0
105. Zhu YX, Benn S, Li ZH, Wei E, Masih-Khan E, Trieu Y, Bali M, McGlade CJ, Claudio JO, Stewart AK. The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades. J Exp Med. 2004; 200(6):737-47. PMID:15381729 PMCID:2211965
106. Chang H, Sloan S, Li D, Zhuang L, Yi QL, Chen CI, Reece D, Chun K, Stewart AK. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. B J Hematol. 2004; 125:64-8. PMID:0
107. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004 Feb 15; 64(4):1546-58. PMID:14989251
108. Claudio JO, Stewart AK. Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma. Am J Pharmacogenomics. 2005; 5(1):35-43. PMID:15727487
109. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. CHIR-258, a novel multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005; 105(7):2941-8. PMID:15598814
110. Shaughnessy Jr J, Zhan F, Barlogie B, Stewart AK. Gene expression profiling and multiple myeloma. Best Pract Res Clin Haematol. 2005; 18(4):537-52. PMID:16026736
111. Chang H, Qi XY, Samiee S, Yi QL, Chen C, Trudel S, Mikhael J, Reece D, Stewart AK. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant. 2005; 36(9):793-6. PMID:16113669
112. Chang H, Qi C, Yi QL, Reece D, Stewart AK. P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood. 2005; 105(1):358-60. PMID:15339849
113. Chang H, Oi XY, Stewart AK. t(11;14) does not predict long-term survival in myeloma. Leukemia. 2005; 19:1078-9. PMID:15815719
114. You YN, Baxter N, Stewart A, Nelson H. Is local excision adequate for T1 rectal cancer? A nationwide cohort study from the National Cancer Database (NCDB). J Clin Oncol 2005 Jun; 23 (16_suppl):3526 PMID:27944397
115. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood. 2005 Jul; 106(1):353-5. PMID:15761022
116. Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol. 2005 Sep 10; 23(26):6339-44. PMID:16155017
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 35 of 53
117. Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J, Reece D, Chen C, Stewart AK. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol. 2005 Oct; 23(28):7069-73. PMID:16129840
118. Trieu Y, Trudel S, Pond GR, Mikhael J, Jaksic W, Reece DE, Chen CI, Stewart AK. Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc. 2005 Dec; 80(12):1578- 82. PMID:16342650
119. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN, Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005 Dec 6; 143(11):777-84. PMID:16330788
120. Chen CI, Nanji S, Prabhu A, Beheshti R, Yi QL, Sutton D, Stewart AK. Sequential, cycling maintenance therapy for post transplant multiple myeloma. Bone Marrow Transpl. 2006; 37:89-94.
121. Newman LA, Lee CT, Parekh LP, Stewart AK, Thomas CR Jr, Beltran RA, Lucci A, Green B, Ota D, Nelson H, American College of Surgeons Oncology Group (ACOSOG) Special Population Committee. Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee. Cancer. 2006 Jan 1; 106(1):188-95. PMID:16333856 DOI:10.1002/cncr.21592
122. Chang H, Qi XY, Claudio J, Zhuang L, Patterson B, Stewart AK. Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res. 2006 Mar; 30(3):262-5. Epub 2005 Aug 19. PMID:16112193 DOI:10.1016/j.leukres.2005.07.008
123. Van Der Jagt R, Robinson KS, Belch A, Yetisir E, Wells G, Larratt L, Shustik C, Cluck S, Stewart K, Sheridan D, Canadian Leukemia Studies Group. Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group. Leuk Lymphoma. 2006 Apr; 47(4):697-706.
124. Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S, Chumakov I, Singer Y, Chang H, Liang SB, Yayon A. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood. 2006 May 15; 107(10):4039-46. Epub 2006 Feb 07. PMID:16467200 DOI:10.1182/blood-2005-10-4179
125. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006 Aug; 81(8):1047-53. PMID:16901028 DOI:10.4065/81.8.1047
126. Masih-Khan E, Trudel S, Heise C, Li Z, Paterson J, Nadeem V, Wei E, Roodman D, Claudio JO, Bergsagel PL, Stewart AK. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood. 2006 Nov 15; 108(10):3465-71. Epub 2006 Jul 18. PMID:16849642 DOI:10.1182/blood-2006-04- 017087
127. Trudel S, Stewart AK, Li Z, Shu Y, Liang SB, Trieu Y, Reece D, Paterson J, Wang DY, Wen XY. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):621-9. PMID:17255285 DOI:10.1158/1078-0432.CCR-06-1526
128. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia. 2007 Mar; 21(3):529-34. Epub 2007 Jan 18. PMID:17230230 DOI:10.1038/sj.leu.2404516
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 36 of 53
129. Fonseca R, Stewart AK. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther. 2007 Mar; 6(3):802-10. PMID:17363477
130. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc. 2007 Mar; 82(3):323-41. PMID:17352369 DOI:10.4065/82.3.323
131. Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E, National Cancer Institute of Canada Clinical Trials Group. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 Apr 20; 25(12):1570-5 Epub 2007 Mar 12. PMID:17353550 DOI:10.1200/JCO.2006.07.8659
132. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res. 2007 Jun; 31(6):779-82. Epub 2006 Sep 22. PMID:16996589 DOI:10.1016/j.leukres.2006.08.002
133. Wong WW, Clendening JW, Martirosyan A, Boutros PC, Bros C, Khosravi F, Jurisica I, Stewart AK, Bergsagel PL, Penn LZ. Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma. Mol Cancer Ther. 2007 Jun; 6(6):1886-97. PMID:17575117 DOI:10.1158/1535-7163.MCT-06-0745
134. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood. 2007 Jun 15; 109(12):5430-8. Epub 2007 Mar 01. PMID:17332241 DOI:10.1182/blood-2006-10-047951
135. Stewart AK, Fonseca R. Review of molecular diagnostics in multiple myeloma. Expert Rev Mol Diagn. 2007 Jul; 7(4):453-9. PMID:17620051 DOI:10.1586/14737159.7.4.453
136. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007 Aug; 12 (2):131-44 PMID:17692805 PMCID:2083698 DOI:10.1016/j.ccr.2007.07.003
137. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007 Oct; 82(10):1179-84. PMID:17908524 DOI:10.4065/82.10.1179
138. Mao X, Stewart AK, Hurren R, Datti A, Zhu X, Zhu Y, Shi C, Lee K, Tiedemann R, Eberhard Y, Trudel S, Liang S, Corey SJ, Gillis LC, Barber DL, Wrana JL, Ezzat S, Schimmer AD. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood. 2007 Dec 1; 110(12):4047-54 Epub 2007 Sep 17. PMID:17875808 DOI:10.1182/blood-2007-05- 088666
139. Chesi M, Robbiani DF, Sebag M, Chng WJ, Affer M, Tiedemann R, Valdez R, Palmer SE, Haas SS, Stewart AK, Fonseca R, Kremer R, Cattoretti G, Bergsagel PL. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008 Feb; 13 (2):167-80 PMID:18242516 PMCID:2255064 DOI:10.1016/j.ccr.2008.01.007
140. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P, ASH/FDA Panel. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb; 22(2):231-9. Epub 2007 Nov 1 PMID:17972944 DOI:10.1038/sj.leu.2405016
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 37 of 53
141. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, Chng WJ, Ketterling RP, Gertz MA, Henderson K, Greipp PR, Dispenzieri A, Lacy MQ, Rajkumar SV, Bergsagel PL, Stewart AK, Fonseca R. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008 May; 22 (5):1044-52 Epub 2008 Jan 24 PMID:18216867 PMCID:3893817 DOI:10.1038/leu.2008.4
142. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest 2008 May; 118 (5):1750-64 PMID:18431519 PMCID:2323188 DOI:10.1172/JCI34149
143. for AJCC 7th Ed'n Hindgut Taskforce (HTF), Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. TN categorization for rectal and colon cancers based on national survival outcome data. J Clin Oncol 2008 May 20; 26 (15_suppl):4020 PMID:27949317
144. Mao X, Liang SB, Hurren R, Gronda M, Chow S, Xu GW, Wang X, Beheshti Zavareh, Jamal N, Messner H, Hedley DW, Datti A, Wrana JL, Zhu Y, Shi CX, Lee K, Tiedemann R, Trudel S, Stewart AK, Schimmer AD. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1; 112(3):760-9. Epub 2008 May 23 PMID:18502826 DOI:10.1182/blood-2008-02-142687
145. Reece DE, Rodriguez GP, Chen C, Trudel S, Kukreti V, Mikhael J, Pantoja M, Xu W, Stewart AK. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008 Oct 10; 26(29):4777-83. Epub 2008 Jul 21. PMID:18645194 DOI:10.1200/JCO.2007.14.2372
146. Ghobrial IM, Stewart AK. ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma? Hematology Am Soc Hematol Educ Program. 2009; 587-9. PMID:20008243 DOI:10.1182/asheducation-2009.1.587
147. Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, Petrucci MT, Musto P, Komarnicki M, Stewart AK. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol. 2009 Jan; 144(2):169-75. Epub 2008 Nov 19. PMID:19036114 DOI:10.1111/j.1365-2141.2008.07409.x
148. Stewart AK. Novel therapies for relapsed myeloma. Hematology Am Soc Hematol Educ Program 2009; 578- 86 PMID:20008242 DOI:10.1182/asheducation-2009.1.578
149. Chen C, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, Wright JJ, Powers J, Walsh W, Eisenhauer E. Bortezomib in relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):74-6. PMID:19362979 DOI:10.3816/CLM.2009.n.019
150. Braggio E, Keats JJ, Leleu X, Wier SV, Jimenez-Zepeda VH, Schop RF, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. High-resolution genomic analysis in Waldenstrom's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma 2009 Mar; 9 (1):39-42 PMID:19362969 PMCID:3646570 DOI:10.3816/CLM.2009.n.009
151. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, Carpten J, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res 2009 Apr 15; 69 (8):3579-88 Epub 2009 Apr 07 PMID:19351844 PMCID:2782932 DOI:10.1158/0008-5472.CAN-08-3701
152. Tiedemann RE, Schmidt J, Keats JJ, Shi CX, Zhu YX, Palmer SE, Mao X, Schimmer AD, Stewart AK. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood 2009 Apr 23; 113 (17):4027-37 Epub 2008 Dec 18 PMID:19096011 PMCID:3952546 DOI:10.1182/blood-2008-09-179796
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 38 of 53
153. Multiple Myeloma Research Consortium (MMRC), Vij R, Wang M, Orlowski R, Stewart AK, Jagannath S, Kukreti V, Le MH, Kunkel L, Siegel D. PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update. J Clin Oncol 2009 May 20; 27 (15_suppl):8537 PMID:27960932
154. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009 Jul; 23 (7):1337-41 Epub 2009 Feb 19 PMID:19225538 PMCID:2711213 DOI:10.1038/leu.2009.26
155. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009 Jul 16; 114 (3):518-21 Epub 2009 Mar 26 PMID:19324902 PMCID:2713462 DOI:10.1182/blood-2009-01-202010
156. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009 Oct 20; 27 (30):5008-14 Epub 2009 Aug 31 PMID:19720894 DOI:10.1200/JCO.2009.23.6802
157. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7085-91. Epub 2009 Nov 10. PMID:19903785 DOI:10.1158/1078-0432.CCR-09-0822
158. International Myeloma Working Group, Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, Morgan G, Van Ness B, Chesi M, Minvielle S, Neri A, Barlogie B, Kuehl WM, Liebisch P, Davies F, Chen-Kiang S, Durie BG, Carrasco R, Sezer O, Reiman T, Pilarski L, Avet-Loiseau H. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009 Dec; 23 (12):2210-21 Epub 2009 Oct 01 PMID:19798094 PMCID:2964268 DOI:10.1038/leu.2009.174
159. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009 Dec; 84 (12):1095-110 PMID:19955246 PMCID:2787395 DOI:10.4065/mcp.2009.0603
160. Stewart AK, Richardson PG, San-Miguel JF. How I treat multiple myeloma in younger patients. Blood. 2009 Dec 24; 114(27):5436-43. Epub 2009 Oct 27. PMID:19861683 DOI:10.1182/blood-2009-07-204651
161. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010 Jan; 24(1):22-32. Epub 2009 Nov 12. PMID:19907437 DOI:10.1038/leu.2009.236
162. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2010 Feb 18; 115 (7):1343- 50 Epub 2009 Dec 11 PMID:20008302 PMCID:2826759 DOI:10.1182/blood-2009-08-239046
163. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010 Feb 25; 115 (8):1594-604 Epub 2009 Dec 07 PMID:19996089 PMCID:2830764 DOI:10.1182/blood-2009-09-243980
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 39 of 53
164. Wang D, Stewart AK, Zhuang L, Zhu Y, Wang Y, Shi C, Keating A, Slutsky A, Zhang H, Wen XY. Enhanced adaptive immunity in mice lacking the immunoinhibitory adaptor Hacs1. FASEB J. 2010 Mar; 24(3):947-56. Epub 2009 Nov 18. PMID:19923443 DOI:10.1096/fj.09-140806
165. Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J, Sonneveld P, Cavo M, Boccadoro M, Palumbo A, Tosi P, Harousseau JL, Attal M, Barlogie B, Stewart AK, Durie B. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010 Mar 20; 28(9):1599-605. Epub 2010 Feb 22. PMID:20177027 DOI:10.1200/JCO.2009.25.2114
166. Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc 2010 Jun; 85 (6):532-7 PMID:20511484 PMCID:2878257 DOI:10.4065/mcp.2009.0677
167. Gay F, Rajkumar SV, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ, Chen-Kiang S, Roy V, Jayabalan DS, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Niesvizky R. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low- dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 2010 Sep; 85 (9):664-9 PMID:20645430 PMCID:3956597 DOI:10.1002/ajh.21777
168. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010 Sep; 85 (9):824-33 Epub 2010 Aug 11 PMID:20702770 PMCID:2931618 DOI:10.4065/mcp.2010.0304
169. Gay F, Vincent Rajkumar, Falco P, Kumar S, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart, Palumbo A. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. Eur J Haematol. 2010 Sep; 85(3):200-8. Epub 2010 May 08. PMID:20477865 DOI:10.1111/j.1600-0609.2010.01469.x
170. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV, Buadi F. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010 Nov; 24 (11):1934-9 Epub 2010 Sept 09 PMID:20827286 PMCID:2978257 DOI:10.1038/leu.2010.190
171. Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke, Acharya M, Zannikos P, Keith Stewart. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011 Jan; 67(1):57-67. Epub 2010 Mar 20. PMID:20306195 DOI:10.1007/s00280-010-1283-3
172. Chang XB, Stewart AK. What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol 2011; 2 (3):287-94 Epub 2011 Sept 10 PMID:22003441 PMCID:3193296
173. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72. PMID:21430775 PMCID:3560292 DOI:10.1038/nature09837
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 40 of 53
174. Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, Stewart AK. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 2011 Apr 07; 117 (14):3847-57 Epub 2011 Feb 02 PMID:21289309 PMCID:3083298 DOI:10.1182/blood-2010-08-304022
175. Khan ML, Stewart AK. Carfilzomib: a novel second-generation proteasome inhibitor. Future Oncol 2011 May; 7 (5):607-12 PMID:21568676 PMCID:3931449 DOI:10.2217/fon.11.42
176. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel, Crowley J, Avet-Loiseau H, International Myeloma. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 5; 117(18):4696-700. Epub 2011 Feb 03. PMID:21292777 PMCID:3293763 DOI:10.1182/blood-2010-10-300970
177. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7. PMID:21477075 DOI:10.1111/j.1600-0609.2011.01602.x
178. Geyer HL, Viggiano RW, Lacy MQ, Witzig TE, Leslie KO, Mikhael JR, Stewart K. Acute lung toxicity related to pomalidomide. Chest 2011 Aug; 140 (2):529-33 PMID:21813533 DOI:10.1378/chest.10-2082
179. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J, Laumann K, Greipp PR, Lust JA, Gertz MA, Zeldenrust SR, Bergsagel PL, Reeder CB, Witzig TE, Fonseca R, Russell SJ, Mikhael JR, Dingli D, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011 Aug; 86 (8):640-5 Epub 2011 May 31 PMID:21630308 PMCID:3901994 DOI:10.1002/ajh.22053
180. Jimenez-Zepeda VH, Heilman RL, Engel RA, Carey EJ, Freeman C, Rakela J, Mulligan DC, Fonseca R, Stewart AK. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation. 2011 Sep 15; 92(5):570-4. PMID:21712755 DOI:10.1097/TP.0b013e318225db2c
181. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Stewart AK, Laumann K, Mandrekar SJ, Reeder C, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011 Sep 15; 118 (11):2970-5 Epub 2011 June 20 PMID:21690557 PMCID:3291492 DOI:10.1182/blood-2011-04-348896
182. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL, Orlowski RZ, Stewart AK. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011 Nov 03; 118 (18):4771-9 Epub 2011 Aug 22 PMID:21860026 PMCID:3208291 DOI:10.1182/blood-2011-05-356063
183. Stewart AK. Monoclonal protein screening prior to solid organ transplant. Transplantation. 2011 Dec 27; 92(12):e66. PMID:22158470 DOI:10.1097/TP.0b013e31823a243f
184. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One. 2012; 7(10):e43192. Epub 2012 Oct 10. PMID:23071490 PMCID:3468610 DOI:10.1371/journal.pone.0043192
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 41 of 53
185. International Myeloma Working Group, Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012 Jan; 26 (1):149-57 Epub 2011 July 29 PMID:21799510 PMCID:4109061 DOI:10.1038/leu.2011.196
186. Khan ML, Reeder CB, Kumar SK, Lacy MQ, Reece DE, Dispenzieri A, Gertz MA, Greipp P, Hayman S, Zeldenhurst S, Dingli D, Lust J, Russell S, Laumann KM, Mikhael JR, Leif Bergsagel P, Fonseca R, Vincent Rajkumar S, Keith Stewart, Keith Stewart A. A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 2012 Feb; 156 (3):326-33 Epub 2011 Nov 23 PMID:22107129 DOI:10.1111/j.1365-2141.2011.08949.x
187. Tiedemann RE, Zhu YX, Schmidt J, Shi CX, Sereduk C, Yin H, Mousses S, Stewart AK. Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome. Cancer Res. 2012 Feb 1; 72(3):757-68. Epub 2011 Dec 06. PMID:22147262 PMCID:3622723 DOI:10.1158/0008-5472.CAN-11-2781
188. Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel, Barlogie B, Morgan G, Sonneveld P, Spencer A, Andersen KC, Facon T, Stewart KA, Einsele H, Mateos MV, Wijermans P, Waage A, Beksac M, Richardson PG, Hulin C, Niesvizky R, Lokhorst H, Landgren O, Bergsagel PL, Orlowski R, Hinke A, Cavo M, Attal M, International Myeloma. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012 Mar 29; 119(13):3003-15. Epub 2012 Jan 23. PMID:22271445 PMCID:3321864 DOI:10.1182/blood-2011-11-374249
189. Stewart AK. Novel therapeutics in multiple myeloma. Hematology 2012 Apr; 17 Suppl 1:S105-8 PMID:22507794 PMCID:3905954 DOI:10.1179/102453312X13336169156131
190. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, Stewart AK, Bergsagel PL, Fonseca R. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012 May 10; 119 (19):4391-4 Epub 2012 Feb 13 PMID:22331188 PMCID:3557400 DOI:10.1182/blood-2011-11-390930
191. Kumar S, Flinn I, Richardson PG, Hari P, Callander N, Noga SJ, Stewart AK, Turturro F, Rifkin R, Wolf J, Estevam J, Mulligan G, Shi H, Webb IJ, Rajkumar SV. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012 May 10; 119(19):4375-82. Epub 2012 Mar 15. PMID:22422823 DOI:10.1182/blood- 2011-11-395749
192. Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, Allred J, Laumann KM, Bergsagel LP, Dingli D, Mikhael JR, Reeder CB, Stewart AK, Zeldenrust SR, Greipp PR, Lust JA, Fonseca R, Russell SJ, Rajkumar SV, Dispenzieri A. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 2012 May 24; 119 (21):4860-7 Epub 2012 Apr 13 PMID:22504925 PMCID:3418771 DOI:10.1182/blood-2012-01-407791
193. Dispenzieri A, Buadi F, Laumann K, LaPlant B, Hayman SR, Kumar SK, Dingli D, Zeldenrust SR, Mikhael JR, Hall R, Rajkumar SV, Reeder C, Fonseca R, Bergsagel PL, Stewart AK, Roy V, Witzig TE, Lust JA, Russell SJ, Gertz MA, Lacy MQ. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 2012 Jun 07; 119 (23):5397-404 Epub 2012 Apr 04 PMID:22493299 PMCID:3369677 DOI:10.1182/blood-2012-02- 413161
194. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70. Epub 2012 May 03. PMID:22555973 DOI:10.1182/blood-2012-03-414359
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 42 of 53
195. Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M, Stewart AK, Johnstone RW, Bergsagel PL. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012 Jul 12; 120 (2):376-85 Epub 2012 Mar 26 PMID:22451422 PMCID:3398763 DOI:10.1182/blood- 2012-02-412783
196. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL. Clonal competition with alternating dominance in multiple myeloma. Blood 2012 Aug 2; 120 (5):1067-76 Epub 2012 Apr 12 PMID:22498740 PMCID:3412330 DOI:10.1182/blood-2012-01-405985
197. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012 Aug 2; 120 (5):1060-6 Epub 2012 Apr 23 PMID:22529291 PMCID:3412329 DOI:10.1182/blood-2012-01-405977
198. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48. Epub 2012 Jul 30. PMID:22845873 DOI:10.1111/j.1365-2141.2012.09232.x
199. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):310-8. PMID:23040437 DOI:10.1016/j.clml.2012.08.003
200. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan- Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 4; 120(14):2817-25. Epub 2012 Jul 25. PMID:22833546 DOI:10.1182/blood-2012-05-425934
201. White DJ, Bahlis NJ, Marcellus DC, Belch A, Stewart AK, Chen C, Kovacs MJ, Macdonald DA, Reece DE, Reiman T, Harnett E, Meyer RM, Chapman JA, Couban S. Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):19-24. Epub 2012 Nov 07. PMID:23141150 DOI:10.1016/j.clml.2012.08.009
202. Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013 Feb 7; 121(6):893-7. PMID:23393020 DOI:10.1182/blood-2012- 10-459883
203. Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, Rubinger M, Cantin G, Song K, Tompkins KA, Marcellus DC, Lacy MQ, Sussman J, Reece D, Brundage M, Harnett EL, Shepherd L, Chapman JA, Meyer RM. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 2013 Feb 28; 121 (9):1517-23 Epub 2013 Jan 07 PMID:23297129 PMCID:3587317 DOI:10.1182/blood-2012-09-451872
204. Mayo Clinic, Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013 Apr; 88 (4):360-76 PMID:23541011 DOI:10.1016/j.mayocp.2013.01.019
205. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 2013 Apr; 54 (4):683-7 Epub 2012 Sept 28 PMID:22966948 PMCID:3931443 DOI:10.3109/10428194.2012.728597
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 43 of 53
206. Braggio E, Egan JB, Fonseca R, Stewart AK. Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J 2013 Jul 19; 3:e127 Epub 2013 July 19 PMID:23872706 PMCID:3730204 DOI:10.1038/bcj.2013.26
207. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013 Sep 9; 24(3):289-304. PMID:24029229 DOI:10.1016/j.ccr.2013.08.009
208. Schmidt J, Braggio E, Kortuem KM, Egan JB, Zhu YX, Xin CS, Tiedemann RE, Palmer SE, Garbitt VM, McCauley D, Kauffman M, Shacham S, Chesi M, Bergsagel PL, Stewart AK. Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT- 276. Leukemia 2013 Dec; 27 (12):2357-65 Epub 2013 June 11 PMID:23752175 PMCID:3922416 DOI:10.1038/leu.2013.172
209. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan- Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6. Epub 2013 May 14. PMID:23670297 PMCID:3865533 DOI:10.1038/leu.2013.152
210. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013 Dec 19; 122 (26):4172-81 Epub 2013 Oct 21 PMID:24144641 PMCID:3952477 DOI:10.1182/blood-2013-08-520890
211. Schuster SR, Kortuem KM, Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Ahmann G, Kumar S, Rajkumar SV, Mikhael J, Laplant B, Champion MD, Laumann K, Barlogie B, Fonseca R, Bergsagel PL, Lacy M, Stewart AK. The clinical significance of cereblon expression in multiple myeloma. Leuk Res 2014 Jan; 38 (1):23-8 Epub 2013 Sept 05 PMID:24129344 PMCID:3905958 DOI:10.1016/j.leukres.2013.08.015
212. Egan JB, Barrett MT, Champion MD, Middha S, Lenkiewicz E, Evers L, Francis P, Schmidt J, Shi CX, Van Wier S, Badar S, Ahmann G, Kortuem KM, Boczek NJ, Fonseca R, Craig DW, Carpten JD, Borad MJ, Stewart AK. Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements. PLoS One 2014; 9 (2):e87113 Epub 2014 Feb 05 PMID:24505276 PMCID:3914808 DOI:10.1371/journal.pone.0087113
213. Multiple Myeloma Research Consortium, Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Getz G, Golub TR. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014 Jan 13; 25 (1):91-101 PMID:24434212 PMCID:4241387 DOI:10.1016/j.ccr.2013.12.015
214. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, McCullough AE, Barrett MT, Hunt K, Patel MD, Young SW, Collins JM, Silva AC, Condjella RM, Block M, McWilliams RR, Lazaridis KN, Klee EW, Bible KC, Harris P, Oliver GR, Bhavsar JD, Nair AA, Middha S, Asmann Y, Kocher JP, Schahl K, Kipp BR, Barr Fritcher EG, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Phillips L, McDonald J, Adkins J, Mastrian SD, Placek P, Watanabe AT, Lobello J, Han H, Von Hoff D, Craig DW, Stewart AK, Carpten JD. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet 2014 Feb; 10 (2):e1004135 Epub 2014 Feb 13 PMID:24550739 PMCID:3923676 DOI:10.1371/journal.pgen.1004135
215. Kumar SK, Mikhael J, Laplant B, Lacy MQ, Buadi FK, Dingli D, Gertz MA, Laumann K, Miceli T, Mahlman M, Bergsagel LP, Hayman SR, Reeder C, Stewart AK, Dispenzieri A, Gastineau DA, Winters JL. Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. Bone Marrow Transplant 2014 Feb; 49 (2):201-5 Epub 2013 Nov 04 PMID:24185588 PMCID:3946357 DOI:10.1038/bmt.2013.175
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 44 of 53
216. Liang WS, Aldrich J, Nasser S, Kurdoglu A, Phillips L, Reiman R, McDonald J, Izatt T, Christoforides A, Baker A, Craig C, Egan JB, Chase DM, Farley JH, Bryce AH, Stewart AK, Borad MJ, Carpten JD, Craig DW, Monk BJ. Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing. Int J Gynecol Cancer. 2014 Feb; 24(2):329-38. PMID:24418928 PMCID:3921261 DOI:10.1097/IGC.0000000000000049
217. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol 2014 Feb 20; 32 (6):587-600 Epub 2014 Jan 13 PMID:24419113 PMCID:3918540 DOI:10.1200/JCO.2013.48.7934
218. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW, Lindor NM, McCormick JB, McWilliams RR, Parker AS, Riegert- Johnson DL, Rohrer Vitek CR, Schahl KA, Schultz C, Stewart K, Then GC, Wieben ED, Farrugia G. Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet. 2014 Mar; 166C(1):15-23. Epub 2014 Mar 10. PMID:24616301 DOI:10.1002/ajmg.c.31387
219. Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai) 2014 Mar; 46 (3):240-53 Epub 2013 Dec 29 PMID:24374776 PMCID:4357794 DOI:10.1093/abbs/gmt142
220. Patrick O'Neill B, Braggio E, O'Neill BP, Van Wier S, Ojha J, McPhail E, Asmann Y, Egan J, Ayres da Silva J, Schiff D, Lopes MB, Valdez R, Tibes R, Eckloff B, Stewart AK, Fonseca R. Genome-wide analysis uncovers recurrent alterations in primary central nervous system lymphomas (pcnsl). Neuro Oncol. 2014 Jul; 16 Suppl 3:iii43. PMID:25165333 PMCID:4144657 DOI:10.1093/neuonc/nou209.7
221. Zhu YX, Braggio E, Shi CX, Kortuem KM, Bruins LA, Schmidt JE, Chang XB, Langlais P, Luo M, Jedlowski P, LaPlant B, Laumann K, Fonseca R, Bergsagel PL, Mikhael J, Lacy M, Champion MD, Stewart AK. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 2014 Jul 24; 124 (4):536-45 Epub 2014 June 09 PMID:24914135 PMCID:4110660 DOI:10.1182/blood- 2014-02-557819
222. Kortuem KM, Zidich K, Schuster SR, Khan ML, Jimenez-Zepeda VH, Mikhael JR, Fonseca R, Stewart AK. Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma. Clin Lymphoma Myeloma Leuk 2014 Aug; 14 (4):284-290.e5 Epub 2013 Dec 28 PMID:24565465 PMCID:4092053 DOI:10.1016/j.clml.2013.12.015
223. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 2014 Aug; 28 (8):1657-65 Epub 2014 Jan 23 PMID:24451410 PMCID:4131248 DOI:10.1038/leu.2014.44
224. Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC. A phase ib multicentre dose-determination study of bhq880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014 Nov; 167(3):366-75. PMID:25139740
225. Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. 2014 Nov 17. [Epub ahead of print] DOI:10.1111/ejh.12491
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 45 of 53
226. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014 Dec; 15 (13):1503-12 Epub 2014 Nov 14 PMID:25456369 DOI:10.1016/S1470-2045(14)71125-8
227. Champion MD, Hlady RA, Yan H, Evans J, Nie J, Lee JH, Bogenberger J, Nandakumar K, Davila J, Moore R, Nair A, O'Brien D, Zhu YX, Kortum KM, Ordog T, Zhang Z, Joseph RW, Stewart AK, Kocher JP, Jonasch E, Robertson KD, Tibes R, Ho TH. Bioinformatics strategies for identifying regions of epigenetic deregulation associated with aberrant transcript splicing and RNA-editing. BIOINFORMATICS 2015 - 6th International Conference on Bioinformatics Models, Methods and Algorithms, Proceedings; Part of 8th International Joint Conference on Biomedical Engineering Systems and Technologies, BIOSTEC 2015. 2015:163-70. DOI:10.5220/0005248001630170
228. Stewart AK. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma. Future Oncol 2015; 11 (15):2121-36 Epub 2015 June 30 PMID:26125319 DOI:10.2217/fon.15.123
229. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2):142-52. PMID:25482145
230. Mayo Phase 2 Consortium, Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood 2015 Jan 15; 125 (3):443-8 Epub 2014 Nov 13 PMID:25395429 PMCID:4296007 DOI:10.1182/blood-2014-05-573741
231. Zhu YX, Yin H, Bruins LA, Shi CX, Jedlowski P, Aziz M, Sereduk C, Kortuem KM, Schmidt JE, Champion M, Braggio E, Keith Stewart A. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. Blood 2015 Jan 15; 125 (3):483-91 Epub 2014 Nov 13 PMID:25395420 PMCID:4296009 DOI:10.1182/blood-2014-05-577130
232. Kortum KM, Langer C, Monge J, Bruins L, Egan JB, Zhu YX, Shi CX, Jedlowski P, Schmidt J, Ojha J, Bullinger L, Liebisch P, Kull M, Champion MD, Van Wier S, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in - 17p high risk disease. Br J Haematol 2015 Feb; 168 (4):507-10 Epub 2014 Oct 10 PMID:25302557 PMCID:4314325 DOI:10.1111/bjh.13171
233. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015 Mar 26; 125 (13):2068-74 Epub 2015 Jan 27 PMID:25628469 PMCID:4375104 DOI:10.1182/blood-2014-12-615187
234. Mikhael JR, Reeder CB, Libby EN, Costa LJ, Bergsagel PL, Buadi F, Mayo A, Nagi Reddy SK, Gano K, Dueck AC, Stewart AK. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol 2015 Apr; 169 (2):219-27 Epub 2015 Feb 13 PMID:25683772 PMCID:4521972 DOI:10.1111/bjh.13296
235. Kortum KM, Langer C, Monge J, Bruins L, Zhu YX, Shi CX, Jedlowski P, Egan JB, Ojha J, Bullinger L, Kull M, Ahmann G, Rasche L, Knop S, Fonseca R, Einsele H, Stewart AK, Braggio E. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P). Ann Hematol 2015 Jul; 94 (7):1205-11 Epub 2015 Mar 07 PMID:25743686 PMCID:4655812 DOI:10.1007/s00277-015-2344-9
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 46 of 53
236. Seggewiss-Bernhardt R, Bargou RC, Goh YT, Stewart AK, Spencer A, Alegre A, Blade J, Ottmann OG, Fernandez-Ibarra C, Lu H, Pain S, Akimov M, Iyer SP. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer 2015 Jul 1; 121 (13):2185-92 Epub 2015 Mar 24 PMID:25809731 DOI:10.1002/cncr.29339
237. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81. PMID:26250727 DOI:10.1016/j.mayocp.2015.06.009
238. Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J 2015 Aug 14; 5:e338 PMID:26275080 PMCID:4558585 DOI:10.1038/bcj.2015.60
239. Kortum KM, Zhu YX, Shi CX, Jedlowski P, Stewart AK. Cereblon binding molecules in multiple myeloma. Blood Rev 2015 Sep; 29 (5):329-34 Epub 2015 Mar 27 PMID:25843596 DOI:10.1016/j.blre.2015.03.003
240. Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, da Silva JA, Schiff D, Lopes MB, Decker PA, Valdez R, Tibes R, Eckloff B, Witzig TE, Stewart AK, Fonseca R, O'Neill BP. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clin Cancer Res 2015 Sep 1; 21 (17):3986-94 Epub 2015 May 19 PMID:25991819 PMCID:4558226 DOI:10.1158/1078-0432.CCR-14-2116
241. Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood 2015 Sep 10; 126 (11):1294-301 Epub 2015 July 08 PMID:26157076 PMCID:4566809 DOI:10.1182/blood-2014-12-613927
242. Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P, Kalimi G, Cai C, Shi M, Scott JW, Stewart AK. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol 2015 Oct; 95 (4):316-24 Epub 2015 Jan 22 PMID:25402977 DOI:10.1111/ejh.12491
243. Braggio E, Kortum KM, Stewart AK. SnapShot: Multiple Myeloma. Cancer Cell 2015 Nov 9; 28 (5):678.e1 PMID:26555176 PMCID:4864595 DOI:10.1016/j.ccell.2015.10.014
244. Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, Alexeeva Y, Facon T, Stewart A, Feng A, Braun A, Balakumaran A, Roodman GD. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer.2016 Jan;
245. Raje N, Vadhan-Raj S, Willenbacher W, Terpos E, Hungria V, Spencer A, Alexeeva Y, Facon T, Stewart AK, Feng A, Braun A, Balakumaran A, Roodman GD. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer J 2016 Jan 08; 6:e378 PMID:26745852 PMCID:4742634 DOI:10.1038/bcj.2015.96
246. Rosenthal A, Luthi J, Belohlavek M, Kortum KM, Mookadam F, Mayo A, Fonseca R, Bergsagel PL, Reeder CB, Mikhael JR, Stewart AK. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J 2016 Jan 15; 6:e384 PMID:26771810 PMCID:4742629 DOI:10.1038/bcj.2015.112
247. Kortuem KM, Braggio E, Bruins L, Barrio S, Shi CS, Zhu YX, Tibes R, Viswanatha D, Votruba P, Ahmann G, Fonseca R, Jedlowski P, Schlam I, Kumar S, Bergsagel PL, Stewart AK. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J 2016 Feb 26; 6:e397 PMID:26918361 PMCID:4771964 DOI:10.1038/bcj.2016.1
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 47 of 53
248. Zhang Z, Tong J, Tang X, Juan J, Cao B, Hurren R, Chen G, Taylor P, Xu X, Shi CX, Du J, Hou J, Wang G, Wu D, Stewart AK, Schimmer AD, Moran MF, Mao X. The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice. Blood 2016 Mar 31; 127 (13):1676-86 Epub 2016 Jan 29 PMID:26825710 DOI:10.1182/blood-2015-07-658203
249. Xu Q, Hou YX, Langlais P, Erickson P, Zhu J, Shi CX, Luo M, Zhu Y, Xu Y, Mandarino LJ, Stewart K, Chang XB. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival. BMC Cancer 2016 May 03; 16:297 PMID:27142104 PMCID:4855823 DOI:10.1186/s12885-016- 2331-0
250. Rosenthal A, Kumar S, Hofmeister C, Laubach J, Vij R, Dueck A, Gano K, Stewart AK. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. Br J Haematol 2016 Jul; 174 (2):323-5 Epub 2015 Sept 25 PMID:26403323 PMCID:4820359 DOI:10.1111/bjh.13765
251. Gaffney DK, King B, Viswanathan AN, Barkati M, Beriwal S, Eifel P, Erickson B, Fyles A, Goulart J, Harkenrider M, Jhingran A, Klopp A, Koh WJ, Lim K, Petersen I, Portelance L, Small W Jr, Stewart A, Wiebe E, Wolfson A, Yashar C, Bosch W. Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma. Int J Radiat Oncol Biol Phys 2016 Jul 15; 95 (4):1191-200 Epub 2016 Feb 21 PMID:27130794 DOI:10.1016/j.ijrobp.2016.02.043
252. Jacobus SJ, Rajkumar SV, Weiss M, Stewart AK, Stadtmauer EA, Callander NS, Dreosti LM, Lacy MQ, Fonseca R. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J 2016 Jul 29; 6 (7):e448 Epub 2016 July 29 PMID:27471864 PMCID:5030380 DOI:10.1038/bcj.2016.55
253. Han M, Murugesan A, Bahlis NJ, Song K, White D, Chen C, Seftel MD, Howsen-Jan K, Reece D, Stewart K, Xie Y, Hay AE, Shepherd L, Djurfeldt M, Zhu L, Meyer RM, Chen BE, Reiman T. A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma. Blood 2016 Aug 04; 128 (5):732-5 Epub 2016 June 23 PMID:27338095 DOI:10.1182/blood-2016-06-716902
254. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova- Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 2016 Sep 01; 128 (9):1174-80 Epub 2016 July 20 PMID:27439911 PMCID:5009511 DOI:10.1182/blood-2016-03-707596
255. Kortum KM, Mai EK, Hanafiah NH, Shi CX, Zhu YX, Bruins L, Barrio S, Jedlowski P, Merz M, Xu J, Stewart RA, Andrulis M, Jauch A, Hillengass J, Goldschmidt H, Bergsagel PL, Braggio E, Stewart AK, Raab MS. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood 2016 Sep 01; 128 (9):1226-33 Epub 2016 July 25 PMID:27458004 DOI:10.1182/blood-2016-02-698092
256. Stewart AK, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol 2016 Sep 06 Epub 2016 Sept 06 PMID:27601539 DOI:10.1200/JCO.2016.66.9648
257. Caraballo PJ, Hodge LS, Bielinski SJ, Stewart AK, Farrugia G, Schultz CG, Rohrer-Vitek CR, Olson JE, St Sauver JL, Roger VL, Parkulo MA, Kullo IJ, Nicholson WT, Elliott MA, Black JL, Weinshilboum RM. Multidisciplinary model to implement pharmacogenomics at the point of care. Genet Med 2016 Sep 22 Epub 2016 Sept 22 PMID:27657685 DOI:10.1038/gim.2016.120
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 48 of 53
258. Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood 2016 Nov 17; 128 (20):2415-2422 Epub 2016 Oct 04 PMID:27702799 PMCID:5114487 DOI:10.1182/blood-2016-05-717769
259. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med 2016 Dec; 22 (12):1411-1420 Epub 2016 Nov 14 PMID:27841872 DOI:10.1038/nm.4229
260. Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J. Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. J Clin Pharmacol 2016 Dec 07 [Epub ahead of print] PMID:27925676
261. Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH. Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Sci Rep 2016 Dec 23; 6 (1):25 PMID:28003660 PMCID:5431338 DOI:10.1038/s41598-016-0021-4
262. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol 2017 Jan 05 [Epub ahead of print] PMID:28056114 DOI:10.1001/jamaoncol.2016.5763
263. Sebastian S, Zhu YX, Braggio E, Shi CX, Panchabhai SC, Van Wier SA, Ahmann GJ, Chesi M, Bergsagel PL, Stewart AK, Fonseca R. Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity. Blood 2017 Feb 23; 129 (8):991-1007 Epub 2016 Dec 27 PMID:28028022 PMCID:5324717 DOI:10.1182/blood-2016-09-738872
264. Caraballo PJ, Hodge LS, Bielinski SJ, Stewart AK, Farrugia G, Schultz CG, Rohrer-Vitek CR, Olson JE, St Sauver JL, Roger VL, Parkulo MA, Kullo IJ, Nicholson WT, Elliott MA, Black JL, Weinshilboum RM. Multidisciplinary model to implement pharmacogenomics at the point of care. Genet Med 2017 Apr; 19 (4):421- 429 Epub 2016 Sept 22 PMID:27657685 PMCID:5362352 DOI:10.1038/gim.2016.120
265. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk- Adapted Therapy. Mayo Clin Proc 2017 Apr; 92 (4):578-598 Epub 2017 Mar 11 PMID:28291589 DOI:10.1016/j.mayocp.2017.01.003
266. Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, Tagtow CM, Jenkins RB, Rumilla KM, Kerr SE, Kocher JA, Beck SA, Fernandez-Zapico ME, Farrugia G, Lazaridis KN, McWilliams RR. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget 2017 Apr 18; 8 (16):27145-27154 PMID:28423702 PMCID:5432324 DOI:10.18632/oncotarget.16057
267. Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S,
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 49 of 53
Aggarwal S, Moreau P, Palumbo A. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J 2017 Apr 21; 7 (4):e554 PMID:28430175 PMCID:5436074 DOI:10.1038/bcj.2017.31
268. Rosenthal A, Dueck AC, Ansell S, Gano K, Conley C, Nowakowski GS, Camoriano J, Leis JF, Mikhael JR, Keith Stewart A, Stewart AK, Inwards D, Dingli D, Kumar S, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. Am J Hematol 2017 May; 92 (5):467-472 Epub 2017 Mar 22 PMID:28230270 DOI:10.1002/ajh.24693
269. Dimopoulos MA, Stewart AK, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol 2017 May; 177 (3):404-413 Epub 2017 Feb 17 PMID:28211560 PMCID:5412871 DOI:10.1111/bjh.14549
270. Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J. Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. J Clin Pharmacol 2017 May; 57 (5):663-677 Epub 2016 Dec 07 PMID:27925676 DOI:10.1002/jcph.850
271. Zhu YX, Shi CX, Bruins LA, Jedlowski P, Wang X, Kortum KM, Luo M, Ahmann J, Braggio E, Stewart AK. Loss of FAM46C promotes cell survival in myeloma. Cancer Res 2017 Jun 15 Epub 2017 June 15 PMID:28619709 DOI:10.1158/0008-5472.CAN-16-3011
272. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma. Blood 2017 Jul 06 Epub 2017 July 06 PMID:28684537 DOI:10.1182/blood-2017-05- 782961
Non-Peer-reviewed Articles 1. Stewart AK, Lassam NJ, Graham FL, Gauldie J, Addison CL, Bailey DJ, Dessureault S, Dube ID, Gallenger S, Krajden M, Rotstein LE, Quirt IC.A phase I study of adenovirus mediated genetransfer of Interleukin 2 cDNA into metastatic breast cancer or melanoma. Human Gene Therapy. 1995; 8:1403-14.
2. Stewart AK, Dube ID, Kamel-Reid S, Keating A.A phase I study of autologous bone marrow transplantation with stem cell bene marking in multiple myeloma. Human Gene Therapy. 1995; 7:107-11.
3. Sutherland DR, Keating A, Stewart AK.Graft assessment of cytokine mobilized peripheral blood progenitors by CD34+ cell enumeration. Autologous Bonne Marrow Transplantation. 1995.
4. Stewart AK, Hawley RG.Immunogene therapy of myeloma. Cancer Research Treatment and Control. 1998; 6:175-9.
5. Hart DNJ, Schultz JL, Stewart AK.Presentation of tumor antigens. Seminars in Hematology. 1998 Mar; 36(1 Suppl 3):21-5.
6. Stewart AK.Gene expressions profiling illuminates myeloma biology. Blood. 2003; 101:4650.
7. Stewart AK.Prognostic staging in myeloma: in search of biology . Blood. 2003; 102:778-9.
8. Stewart AK.Myeloma: a risk-adapted approach to myeloma therapy. ASCO Educational Book. 2008.
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 50 of 53
Book Chapters 1. Stewart AK, Dube ID, Hawley RG. Gene marking and the biology of hematopoietic cell transfer in human clinical trials. In: Blood Cell Biochemistry, Hematopoiesis and Gene Therapy. Vol. 8. 1999. p. 243-68.
2. Stewart AK. Molecular therapy in hematology. In: Provan and Gribben. Molecular Hematology. Blackwell Scientific; 1999. p. 209-24.
3. Chen CI, Stewart AK. Multiple myeloma. In: Rakel and Bope. Conn's Current Therapy 2002. Vol. 5. W.B. Saunders Company; 2001. p. 439-43.
4. Shaughnessy J, Stewart AK. Gene expression profiling and multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC (editors). Myeloma biology and management, third edition. Philadelphia, PA: W.B. Saunders Company; 2004. p. 83-95.
5. Gyorffy S, Gauldie J, Stewart AK, Wen XY. Antiangiogenic gene therapy of cancer. In: Curiel DT, Douglas JT (editors). Cancer gene therapy. Totowa, New Jersey: Humana Press; 2005. p. 261-71.
6. Stewart AK, Medin JA. Molecular therapeutics in hematology . In: Provand and Gribben. Molecular Hematology, Second Edition. 2005. p. 280-97.
7. Mikhael J, Stewart AK. Multiple myeloma and related disorders. In: Young NS, Gerson SL, High KA (editors). Clinical hematology Philadelphia: Mosby/Elsevier; 2006. p. 637-646.
8. Sebag M, Stewart AK. Evidence-based review of therapies in multiple myeloma. In: Crowther MA, et al, editors. Evidence-based hematology. Chichester; Hoboken: Wiley-Blackwell/BMJ Books; 2008. p. 390-5.
9. Jimenez-Zepeda VH, Stewart AK. Fibroblast growth factor receptor 3 and multiple myeloma. In: Lonial S, editor. Myeloma therapy: pursuing the plasma cell. Totowa: Humana; 2008. (Contemporary Hematology.). p. 365-78.
10. Stewart AK. Staging and risk-stratification of multiple myeloma. In: Rajkumar SV, Kyle RA, editors. Treatment of multiple myeloma and related disorders. Cambridge; New York: Cambridge University Press; 2009. p. 18-25.
11. Bergsagel PL, Stewart AK, Russell SJ, Fonseca R. Molecular genetic aspects of plasma cell disorders. In: Greer JP, Arber DA, Glader B, List AF, Means RT, Paraskevas F, Rodgers GM. Wintrobe's Clinical Hematology 13th ed. Wolters Kluwer; 2013. p. 2022-28.
12. Kumar S, Fonseca R, Stewart K. Molecular classification and risk stratification. In: Gertz MA; Rajkumar SV editor. Multiple myeloma: diagnsis and treatment. New York: Springer; 2014. p. 55-64.
13. Bergsagel PL, Stewart AK, Russell SJ, Morice WG. Molecular genetic aspects of plasma cell disorders. In: Greer JP; et al editor. Wintrobe's clinical hematology. Thirteenth Edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014. p. 2022-8.
Commentaries 1. Stewart AK. Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood. 2009 Apr 2; 113(14):3135-6. PMID:19342498 DOI:10.1182/blood-2008-12-173526
2. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen- Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S,
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 51 of 53
Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4. PMID:20118399 DOI:10.4065/mcp.2009.0559
3. Stewart AK. Union of forces advances myeloma care. Blood. 2010 Aug 5; 116(5):674- 5. PMID:20688962 DOI:10.1182/blood-2010-04-281212
4. Stewart AK. Medicine. How thalidomide works against cancer. Science 2014 Jan 17; 343 (6168):256- 7 PMID:24436409 DOI:10.1126/science.1249543
5. Pereira NL, Stewart AK. Clinical Implementation of Cardiovascular Pharmacogenomics. Mayo Clin Proc. 2015 Jun; 90(6):701-4. PMID:26046404 DOI:10.1016/j.mayocp.2015.04.011
Letters 1. Claudio JO, Zhan F, Zhuang L, Khaja R, Zhu YX, Sivananthan K, Trudel S, Masih-Khan E, Fonseca R, Bergsagel PL, Scherer SW, Shaughnessy J, Stewart AK. Expression and mutation status of candidate kinases in multiple myeloma. Leukemia. 2007 May; 21(5):1124-7. Epub 2007 Mar 8. PMID:17344920 DOI:
2. Stewart AK, Chang H, Trudel S, Anderson K, Richardson P, Alsina M, Reece D, Young S, Sable-Hunt A, Li Z, Keats J, Van Wier S, Ahmann G, Price-Troska T, Giusti K, Bergsagel P, Chesi M, Fonseca R. Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia. 2007 Nov; 21(11):2358- 9. Epub 2007 Jun 14. PMID:17568814 DOI:10.1038/sj.leu.2404800
3. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N, Ehlenbeck C, Reeder C, Slack J, Leis JF, Boesiger J, Torloni AS, Fonseca R, Bergsagel PL. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia. 2008 Jun; 22(6):1282-4. Epub 2008 Jan 24. PMID:18216870 DOI:10.1038/sj.leu.2405100
4. Deng H, Tang N, Stief AE, Mehta N, Baig E, Head R, Sleep G, Yang XZ, McKerlie C, Trudel S, Stewart AK, McCart JA. Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus. Leukemia. 2008 Dec; 22(12):2261-4. Epub 2008 May 29. PMID:18509356 DOI:10.1038/leu.2008.120
5. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, Hentz J, Pirooz NA, Piza JG, Tiedemann R, Mikhael JR, Bergsagel PL, Leis JF, Fonseca R, Stewart AK. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010 Apr 22; 115(16):3416- 7. PMID:20413666 DOI:10.1182/blood-2010-02-271676
6. Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R, Phillips L, Baker A, Shi CX, Schmidt J, Liang WS, Craig DW, Carpten JD, Stewart AK. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol. 2013 Jun; 161(5):748-51. Epub 2013 Mar 11. PMID:23480694 DOI:10.1111/bjh.12291
7. Reeder CB, Reece DE, Kukreti V, Mikhael JR, Chen C, Trudel S, Laumann K, Vohra H, Fonseca R, Bergsagel PL, Leis JF, Tiedemann R, Stewart AK. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br J Haematol. 2014 Nov; 167(4):563-5. Epub 2014 Jun 30. PMID:24974945 DOI:10.1111/bjh.13004
8. Roy V, Stewart AK, Bergsagel PL, Dispenzieri A, Laumann K, Allred J, Lacy MQ, Fonseca R, Reeder CB, Kumar S, Rivera CE, Gertz MA, Buadi FK, Hayman SR, Rajkumar SV. Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation. Blood Cancer J. 2015; 5:e294. Epub 2015 Mar 20. PMID:25794130 DOI:10.1038/bcj.2015.23
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 52 of 53
9. Shi CX, Kortum KM, Zhu YX, Jedlowski P, Bruins L, Braggio E, Stewart AK. Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma. Haematologica 2015 Aug; 100 (8):e315-7 Epub 2015 May 14 PMID:25975838 DOI:10.3324/haematol.2015.124297
Abstracts 1. Jimenez-Zepeda VH, Reeder CB, Mikhael JR, Dispenzieri A, Gertz M, Mayo A, Spong J, Fanning JI, Bergsagel L, Stewart AK, Fonseca R. Cyclophosphamide, bortezomib and dexamethasone (CyBORD) induces rapid and complete responses in patients with amyloidosis not eligible for peripheral blood stem cell transplant. Blood. 2009 Nov 20; 114(22):737.
2. Stewart AK, Jacobus S, Fonseca R, Weiss M, Callander NS, Chanan-Khan AA, Rajkumar SV. E1a06: a phase iii trial comparing melphalan, prednisone, and thalidomide (mpt) versus melphalan, prednisone, and lenalidomide (mpr) in newly diagnosed multiple myeloma mm). Haematologica. 2014 Jun 1; 99:220.
3. Egan JB, Bryce AH, Champion MD, Liang WS, Fonseca R, McCullough AE, Barrett MT, Hunt K, Condjella RM, McWilliams RR, Mastrian SD, LoBello J, Von Hoff D, Craig DW, Stewart AK, Carpten JD, Borad MJ. Indices of actionability and clinical utility in a clia-enabled study of whole genome/exome/rna sequencing in 33 cancer patients: actionable vs. utility. Cancer Res. 2014 Oct 1; 74(19).
4. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, Miguel JFS, Ludwig H, Zojwalla N, Tonda ME, Xing B, Moreau P, Palumbo A. Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients (pts) with relapsed multiple myeloma: interim results from aspire, a randomized, open-label, multicenter phase 3 study. Blood. 2014 Dec 6; 124(21):79.
5. Kortuem KM, Stewart AK, Bruins LA, Ahmann G, Vasmatzis G, Rajkumar SV, Kumar S, Dispenzieri A, Lacy MQ, Gertz MA, Fonseca R, Champion M, Bergsagel PL, Braggio E. Development and results of a multiple myeloma specific custom 77-gene mutation panel for clinical targeted sequencing. Blood. 2014 Dec 6; 124(21).
6. Shi CX, Zhu YX, Jedlowski P, Bruins L, Kortuem M, Stewart AK. Ikaros degradation efficiency correlates with response of multiple myeloma (mm) cells to imid therapy and is blocked by proteasome inhibitors. Blood. 2014 Dec 6; 124(21).
7. Lacy MQ, LaPlant BR, Laumann KM, Kumar S, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell S, Dingli D, Go RS, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Ailawadhi S, Chanan-Khan A, Stewart AK, Reeder CB, Rajkumar SV, Mikhael JR. Pomalidomide plus low-dose dexamethasone (pom/dex) in relapsed lenalidomide refractory myeloma: long term follow up and comparison of 2 mg vs 4 mg doses. Blood. 2014 Dec 6; 124(21).
8. Lacy MQ, LaPlant BR, Laumann KM, Kumar S, Gertz MA, Hayman SR, Buadi F, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Ailawadhi S, Chanan-Khan A, Stewart AK, Reeder CB, Rajkumar SV, Mikhael JR. Pomalidomide, bortezomib and dexamethasone (pvd) for patients with relapsed lenalidomide refractory multiple myeloma (mm). Blood. 2014 Dec 6; 124(21):304.
9. Thompson M, Britt RD, Stewart A, Thu J, MacFarlane P, Martin RJ, Pabelick C, Prakash YS. Hyperoxia stimulates brain-derived neurotrophic factor secretion via camp-epac-in developing airway smooth muscle American Journal Of Respiratory And Critical Care Medicine 2015; 191
10. Britt RD, Thompson MA, Stewart A, Vogel ER, Thu J, Karass M, Martin RJ, Pabelick C, Prakash YS. Soluble guanylate cyclase activators reduce bdnf secretion and calcium responses in human fetal airway smooth muscle exposed to hyperoxia American Journal Of Respiratory And Critical Care Medicine 2015; 191
11. Stewart AK, Rajkumar SV, Dimopoulos MA, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Jakubowiak AJ, San-Miguel JF, Zojwalla N, Moreau P, Palumbo A. Interim results from aspire, a randomized,
RE-AIMS 12/22/2016
A Keith Stewart, MB ChB, MBA, MRCP, FRCPC Page 53 of 53
open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Br J Haematol. 2015 Apr; 169:20.
12. Dimopoulos MA, Stewart AK, Rajkumar SV, Masszi T, Oriol A, Hajek R, Rosinol L, Siegel DSD, Mihaylov G, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San Miguel JF, Ludwig H, Zojwalla NJ, Moreau P, Palumbo A. Effect of carfilzomib, lenalidomide, and dexamethasone (krd) vs lenalidomide and dexamethasone (rd) in patients with relapsed multiple myeloma (rmm) by line of therapy: secondary analysis from an interim analysis of the phase iii study aspire (nct01080391). J Clin Oncol. 2015 May 20; 33(15).
13. Rosenthal AC, Fonseca R, Mikhael J, Stewart AK, Mayo A, Chesi M, Kosiorek H, Bergsagel PL. Interim analysis of a phase ii trial of nab-paclitaxel in patients with very advanced relapsed/refractory multiple myeloma (rr-mm). J Clin Oncol. 2015 May 20; 33(15).
14. Dimopoulos MA, Stewart AK, Rajkumar SV, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Zojwalla N, Tonda M, Yang X, Moreau P, Palumbo A. Effect of carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients with relapsed multiple myeloma by line of therapy: interim results from the phase 3 aspire study. Haematologica. 2015 Jun; 100:151-2.
15. Britt R Jr, Thompson MA, Kuipers I, Stewart A, Vogel ER, Thu J, Martin RJ, Pabelick CM, Prakash YS. Soluble guanylate cyclase modulators reduce calcium responses in developing airway smooth muscle exposed to hyperoxia Journal Of Vascular Research 2016; 53:51
Miscellaneous 1. Stewart AK, Patience J. Multiple myeloma: genome sequencing, drug development and the future outlook. [interview] Expert Rev Hematol. 2014 Feb; 7(1):9-11. Epub 2014 Jan 9
Forthcoming 1. Stewart AK, et al. Carfilzomib and the Cardio-Renal System in Myeloma: An Endothelial Effect? Blood Cancer Journal. 2015.
* Indicates that the primary author was a mentee of this author.
RE-AIMS 12/22/2016